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The historiography (the writing of history based on a critical ex-
amination of sources) of the actions, fate and uses of antimicrobial 
drugs (AMDs) in animals, and the science, welfare and economics 
underlying these uses, have been the subject of many thousands of 
articles and many millions of words. This review seeks to summarize 
key aspects of this history. This inevitably involves both selection 
from and compression of the voluminous literature. The review does 
not aim to prosecute past uses in the court of the present, but rather 
seeks to report and analyse “the what, when and why” of the history, 
as a basis for comprehending current uses and enabling better uses 
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The evolutionary process of antimicrobial drug (AMD) uses in animals over a mere 
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and revolution are ongoing, with reports on a range of uses, misuses and abuses 
escalating logarithmically. As well as veterinary therapeutic perspectives (efficacy, 
safety, host toxicity, residues, selection of drug, determination of dose and measure-
ment of outcome in treating animal diseases), there are also broader, nontherapeutic 
uses, some of which have been abandoned, whilst others hopefully will soon be dis-
continued, at least in more developed countries. Although AMD uses for treatment 
of animal diseases will continue, it must: (a) be sustainable within the One Health 
paradigm; and (b) devolve into more prudent, rationally based therapeutic uses. As 
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its scope has been made broader than most recent reviews in this field. Many re-
views have focused on negative aspects of AMD actions and uses, especially on the 
question of antimicrobial resistance. This review recognizes these concerns but also 
emphasizes the many positive aspects deriving from the use of AMDs, including 
the major research-based advances underlying both the prudent and rational use of 
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(3) Nontherapeutic and empirical uses of AMDs (roles of agronomists and veterinar-
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biographies of individuals contributing to the AMD story. A recently 
published Chapter on AMDs in veterinary medicine has outlined the 
main historical timelines of important events and trends in the use 





A comprehensive review of the sulfonamide–diaminopyrimidine 
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metabolite of the pro-drug Prontosil from Bayer, was first prepared 
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but its antimicrobial properties were not recognized (Anonymous, 
2019e). At the time of the discovery of its anti-infectious properties, 
it was not covered by patent restrictions and it therefore became 
available at low cost in veterinary medicine.
The first veterinary use of sulfanilamide was for bovine mastitis 
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cited by Roach and Hignett in their review on treatment of mastitis 
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Prior to the introduction of sulfonamides, the recovery rate was 
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Another sulfonamide innovation was the advent of the routine use 
of AMD incorporation in poultry feeds to prevent coccidiosis with 
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amides demonstrated the correlation between blood concentra-
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as the first veterinary expression of the pivotal pharmacokinetic 
(PK)/PD paradigm.
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tus to comparative veterinary pharmacology, by highlighting major 
differences between domestic species in sulfonamide metabolism, 
distribution and excretion, illustrated by Francis’ comparison of 
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that time, PK data were presented on a categorical scale (crosses) 
to indicate blood concentrations as either relatively high or low 
and relatively long or short persistency of drugs in vivo. Less than 
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 &! ƑՊFolke Rasmussen (1930–) published many early 
studies on sulfonamides in cattle. His scientific contributions 
include the mammary, renal and salivary excretion of drugs, 
bioavailability, residues and tissue tolerance of drug formulations at 
injection sites, focusing predominantly on antimicrobial drugs
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Folke Rasmussen at the University of Copenhagen reported, in 
cattle and goats, that sulfonamides, penicillin, erythromycin and 
penethamate (penicillin) crossed the blood–milk barrier through 
passive diffusion, down the concentration gradient of the union-
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1959; Figure 2). Further evidence of the applicability of the pH 
partition theory and the Henderson–Hasselbalch equation for 
veterinary drugs, including eight sulfonamides, was provided by 
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Franco Faustini, a veterinary pharmacologist at Milano 
University, developed several sulfonamides (on which he held 
many patents), specifically for use in veterinary therapeutics 
Ő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Nouws (Figure 3) published a series of papers on the comparative 
PK of sulfonamides in domestic species and humans, with em-
phasis on: acetylation-deacetylation mechanisms (Nouws, Vree, 
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was affiliated to a meat inspection service and he also published 
landmark papers on sulfonamide residues in meat and milk (Nouws, 
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rimidine combinations. Trimethoprim (TMP) was the first-in-class 
diaminopyrimidine compound. TMP-sulfonamide combinations 
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commercial development because it has, in humans, the same 
elimination half-life as TMP. To achieve optimal synergy, the sul-
famethoxazole:TMP in vivo blood concentration ratio should be 
20:1. This value was obtained with co-trimoxazole (Bactrim©), a 
fixed combination product having a formulation ratio of 5:1, first 
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copied directly, ignoring species PK differences. For example, 
TMP for pigs has been formulated with either sulfadimethoxine 
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combination thus transgressed the objective of sustained syner-
gism by failing to maintain, over the duration of treatment, the 
optimal blood ratio of 20:1. Additionally, large inter-species PD 
differences exist. Using a tissue cage model in calves infected 
with E. coli, it was shown that several concentrations of TMP had 
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unexpected finding was attributed to a high level of thymidine 
in calf serum, thymidine being a known antagonist of the action 
of TMP on some pathogens, including E. coli. These findings ad-
ditionally illustrate the problem of extrapolating data between 
species. In this case, thymidine serum concentration is high in 
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interest in drug residues, notably of antibiotics and their detection 
under meat inspection conditions. His most cited paper was 
on the comparative local tolerance and residue aspects of five 
oxytetracycline formulations in calves, pigs and sheep (Nouws, 
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in several fields: acute phase responses to infections, comparative 
pharmacokinetics, drug metabolism in large animal species with 
particular reference to antimicrobial drugs and pharmacological 
aspects of feed intake in small ruminants
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Currently in veterinary medicine, sulfonamides and their combi-
nation with dihydrofolate reductase inhibitors have been placed in 
1-|;]ou	o=|_;m|blb1uo0b-Ѵ7b1;-7_o1r;u|uorŐő
(see Figure 5
) classification. This is the class of lowest risk in terms of 
public health (Anonymous, 2019a). Hence, there are now oppor-
tunities for re-visiting and optimizing this class of AMD combi-






The early history of AMDs in animals was dominated by agronomi-
cal applications in animal husbandry, with only limited contributions 
from veterinary clinicians and no input of veterinary pharmacologists. 
It must be stressed that the use of AMDs in animals is not synony-
mous with AMD applications in veterinary medicine. Moreover, early 
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Alimentarius Commission (CAC) develops harmonized international food standards to protect consumer health. It established a first Task 




became increasingly focussed on the “One Health” paradigm including AMR and created an OIE List of antimicrobial agents of veterinary 
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Center for Disease Control and Prevention (CDC, link too sick people) and in particular with the Food and Drug Administration (FDA, link 
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and Resistance Analysis Report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial 
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Technical Requirements for Registration of Veterinary Medicinal Products
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agricultural AMD uses were not limited to animal husbandry. They en-
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and other practices, such as the preservation of meat (Deatherage, 
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fish and, according to Britain’s Times newspaper, antibiotic preserva-
tive usage comprised the greatest advance in the field of processing 
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in animal husbandry and veterinary medicine (vide infra), clearly ac-
knowledged this separation between veterinary (therapeutic) and 
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Early AMD incorporation in animal feed had the objective of 
enhancing growth through improved feed conversion efficiency. 
The mechanism of this effect on growth rate remains uncertain 
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erature in animals suggests that growth promotion was the main use 
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animal and dairy science, not veterinary, journals.
The benefit of feed additives as growth promoters was a ser-
endipitous discovery. It commenced with the search for an inex-
pensive source of vitamin B12 in high-value protein fermentation 
cake. As a by-product of the fermentation process, the cake given 
to poultry was intended to improve weight gain and enhance the 
food conversion ratio. In fact, the weight gain was not attributable 
to vitamin B12 but to small amounts of chlortetracycline in the cake 
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approved the use of antibiotics in animal feeds without a veterinary 
prescription. Although more recently questioned, the justification at 
that time was to reduce food prices in a period of postwar austerity 
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the demand for inexpensive protein of animal origin in middle- and 
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Historically, the use of feed additives was accompanied by new 
farming systems, with large groups of animals confined together in 
restricted spaces. This integrated model of production (feed-lots 
and Concentrated Animal Feeding Operations [CAFOs]) originated 
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Confined animal populations are unavoidably exposed to excreta, 
and the price paid was new pathogen risks to both animal and 
human health. Nevertheless, such systems were made possible by 
mass AMD dosing, with the dual goals of high productivity and the 
requirement to control infectious diseases. As quoted by Kirchhelle, 
antibiotics’ “role was that of an universal lubricant” to control dis-
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There were early expressions of concerns for human health, aris-
ing from the widespread use of AMDs in intensive farming practices 
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zontal transfer between bacteria were unknown. Resistance to chlor-
tetracycline was believed to be solely chromosomal and its spread 
solely vertical (hereditary). The dominant opinion was that develop-
ment of resistance to antibiotics at hospitals and in farms was separate 
and unrelated issues. Dangers of hypersensitivity reactions to drug 






separate medicines with watertight barriers. This led to the first reg-
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transfer of resistance, recommendations were based on the belief 
that resistance selection in farm animals was only a local problem. 
In addition, it was believed that resistance would spontaneously 
disappear after discontinuing AMD administration, due to the nat-
ural competition between bacteria that would presumably favour 
susceptible bacteria in the absence of antibiotic selective pres-
sure (fitness cost). Introduction of a new technique, phage typing, 
was destined to radically change this erroneous assumption. As 
some bacteriophages can only infect one or a few bacterial strains, 
phage typing can be used to identify and distinguish different bac-
terial strains of the same species, and thus to trace the source of 
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phage-typing method. They showed that AMD used for growth 
promotion exerted major effects on antibiotic resistance in E. coli 
isolated from pig and chicken faeces. They warned that resistance 
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detailed studies of the bacteriology of the intestinal tract in health 
and disease. He was prescient in expressing early concern on the 
use of antibiotics in livestock, both as food additives to promote 
growth and as prophylactics against infection
ѵՊ|Պ ՊՍ LEES Et aL.
selection on farms could also harm humans indirectly by transfer 
o= u;vbv|-m|0-1|;ub-0;|;;m-mbl-Ѵv-m7_l-mv Ő"lb|_ķƐƖѵѶķ
ƐƖѵƖķƐƖƕƏķƐƖƕƐőĺ
m ƐƖѵƔķ -m bm=Ѵ;m|b-Ѵ r-r;u 0 m7;uvom Ő- o1-Ѵ _bv-
tle-blower) and Naomi Datta was published in the Lancet (Anderson 
ş	-||-ķƐƖѵƔőĺ$_;7bu;1|Ѵ1_-ѴѴ;m];7|_;7olbm-m|r-u-7b]lo=
the sole vertical transmission of resistance. They demonstrated 
the possibility of inter-bacterial horizontal transfer of resistance 
to ampicillin to previously sensitive strains of S. typhimurium and 
E. coli by exchange of extra-chromosomal DNA fragments (now 
known as plasmids). More importantly, they showed for the first 
time that horizontal resistance transfer can occur between bacte-
ria present in animal populations and human-associated bacteria, 
confounding the dogma of an impenetrable barrier between hu-
mans and animals. These findings were revolutionary with respect 
to risk assessment of AMD use for growth promotion. Thus, after 
ƐƖѵƔķv1b;m|b=b1;b7;m1;;v|-0Ѵbv_;7|_-|u;vbv|-m1;1-mmoѴom];u
be considered solely as a phenomenon confined to those farms 
using AMDs. Rather, it indicated the potential global environmen-
tal risks of antibiotic resistance, which has since been confirmed. 
$_bvv-]-ķѴ;-7bm]|o|_;;v|-0Ѵbv_l;m|o=|_;"-mm1ollb||;;ķbv
well documented by Kirchhelle from both sociological and histori-
1-Ѵr;uvr;1|b;vŐbu1__;ѴѴ;ķƑƏƐѶ-őĺ
In this new scientific framework, including the possibility of 
horizontal transfer of resistance, the human health concerns were 
mainly focussed on AMD use for growth promotion, this being the 
largest use of these drugs globally. It was recognized that human 
populations were exposed to antimicrobial-resistant pathogens 
and their resistance genes, both via the food chain and through 
b7;vru;-7 u;Ѵ;-v; bm|o |_; ;mbuoml;m| Ő"bѴ0;u];Ѵ7ķu-_-lķş
ub1;ķƑƏƏѶőĺ
;|;;m ƐƖѵƒ -m7 ƐƖѵƔķ m7;uvom -m7 ;bv Őm7;uvom ş
;bvķƐƖѵƔő7;v1ub0;7bm|_;&-vr;1|-1Ѵ-uubv;ķbm0o|__l-mv
and calves, of isolates of S. typhimurium phage type 29 that were 
multi-resistant. Moreover, there were clear geographical and epide-
miological links between humans and bovines, with emergence of 
resistance to furazolidone, an AMD that, due to its sole use in agri-
culture and veterinary medicine, exerted the role of a tag, signing the 
direction of exchanges from veterinary to human medicine cases. 
Beyond scientific concepts and laboratory findings, several food-
borne dramatic events occurred in the UK with the deaths of dozens 
of children that could not be cured by antibiotic therapy (Kirchhelle, 
ƑƏƐѶ-őĺ$_bv vom7;7 |_;7;-|_hm;ѴѴ =ou |_;1om1;r| |_-|]uo|_
promoters posed no dangers to humans. Arising from both public 
and scientific concerns on this nontherapeutic use of AMDs in ani-
l-Ѵvķ-1ollb||;;-v;v|-0Ѵbv_;7bmƐƖѵѶķm7;u|_;1_-bul-mv_br
o=b1_-;Ѵ;u;7b|_"-mmŐb]u;ƕő-m7;romlovѴm-l;7-=|;u
him. Its terms of reference were as follows: “To obtain information 
about the present and prospective use of antibiotics in animal hus-
bandry and veterinary medicine with the particular reference to the 
phenomenon of infective drug resistance, to consider the implica-






concluded that outbreaks of infection due to S. typhimurium included 
cases in which human disease and death resulted from multi-resist-
ant isolates, which had acquired their resistance through the use of 
antibiotics in animals. The Committee proposed a ban on growth 
promotional use of penicillin, chlortetracycline and oxytetracycline 
and revocation of legislation permitting their use without prescrip-
tion. In addition, for three AMDs used therapeutically, sulfonamides 
as a group, tylosin and nitrofuran, it was recommended that they 
v_oѴ7moѴom];u0;vrrѴb;7b|_o|ru;v1ubr|bomŐ!-m7-ѴѴķƐƖѵƖőĺm
=-1|ķ|_;"-mmu;rou|=-bѴ;7|o=ѴѴ-1hmoѴ;7];|_;1omv;t;m1;v
of horizontal resistance transfer. Not all its recommendations were 




penicillins, a mixture of penicillin/streptomycin and oleandomycin; 
|_;v;;u;u;]Ѵ-|;7=our_-vbm]Ŋo|bmm;ƐƖƕѵŐ|;|u-11Ѵbm;v-m7
r;mb1bѴѴbmvő-m7";r|;l0;uƐƖƕƖŐoѴ;-m7ol1bmőĺ$_;"-mmu;rou|
therefore marked an important milestone in the history of precau-
tionary substance regulation and it was one of the first examples of 
ru;1-|bom-uuor;-mubvhu;]Ѵ-|bomŐbu1__;ѴѴ;ķƑƏƐѶ-őĺ
"_ou|Ѵ-=|;ur0Ѵb1-|bomo=|_;"-mmu;rou|ķbmƐƖƕƑķ-oo7
and Drug Administration (FDA) task force report on antibiotics 
raised the question of possible dangers to public health from the 
 &! ƕՊb1_-;Ѵ;u;7b|_"-mmŐƐƖƑƏŋƐƖƖƏő-v
molbm-|;7-v_-bul-mķbmѴƐƖѵѶķo=|_;obm|ollb||;;
on the use of Antibiotics in Animal Husbandry and Veterinary 
Medicine in the UK, based on his a priori neutral opinion on this 
increasingly controversial topic and his contributions to cell biology
ՊՍ Պ |ՊƕLEES Et aL.
use of AMDs in livestock. It was acknowledged that the use of 
AMDs, especially in growth promotion and when used in sub-ther-
apeutic amounts, favoured the selection and development of 
AMR and “R-factor” bearing bacteria, with animals serving as a 
reservoir of AMD resistant pathogens present in meat (Lehmann, 
ƐƖƕƑőĺ$_;|-vh=ou1;u;1oll;m7;7|_-|u;v|ub1|bomv0;rѴ-1;7om
|_;v;o=	v-v]uo|_ruolo|;uv -m7ķ bm;0u-uƐƖƕƑķ -
proposed policy statement appeared in the Federal Register. The 
=;;7 bm7v|u u;-1|bom-v |_-| |_bv-v 1omf;1|u; Ő)bѴѴb-lvom
ş u-;mvķ ƐƖƕƑő -m7 1-ѴѴ;7 =ou ruoo= o= _-ulĺ m7v|ub-Ѵ =;;7
companies employed, successfully, counter science and pharma-
1;|b1-Ѵ Ѵo00bv|v Őbu1__;ѴѴ;ķ ƑƏƐѶ0őĺ "0v;t;m|Ѵķ v|-=vomķ
from American Cyanamid, continued the debate on implications of 
the use of AMD in livestock, in relation to human health concerns 
Őv|-=vomķƐƖƖƐő-m7-mm;]-|b;1ommo|-|bomvom|_bvv;;u;
denied.
In the mid-late 1990s, concerns were expressed on AMD use 
in farm animals, centring on avoparcin, a glycopeptide used exten-
sively in the EU and Australia as a food additive growth promoter in 
1_b1h;mvķrb]v-m71-||Ѵ;0|mo|bm|_;&"ķ7;|ob|v1-u1bmo];mb1
;==;1|Ő-u|omķƑƏƏƏĸ);];m;uķƐƖƖѶĸ);];m;uķ-u;v|urķ;mv;mķ
-ll;ulķ ş -];uķ ƐƖƖƖőĺ or-u1bm bv v|u1|u-ѴѴ u;Ѵ-|;7 |o
vancomycin and teicoplanin, two AMDs critical, in human med-
icine, for treatment of serious gram-positive bacterial infections, 
especially when resistance or allergy to beta-lactams prevent their 
v;ĺ m |_; ƐƖѶƏvķ -or-u1bm v;-v 1Ѵ-bl;7 |o _-; ];m;u-|;7
vancomycin-resistant enterococci (VRE). It is because its addition 
to animal feeds was associated with the widespread distribution 
of VRE, not only in livestock but also in pets, uncooked chicken 
meat and sewage; glycopeptide resistance of Enterococcus faecium 
occurred on farms where avoparcin had been used (Aarestrup, 




that VRE harbouring the same vanA and vanB genes as those found 
in animals were present in the faeces of nonhospitalized patients 
bmuor;ĺ$_bv-vmo||_;1-v;bm|_;&"ķvrrou|bm]|_;b;
that, in Europe, people were exposed to VRE from animal or en-
vironmental sources (Barton, 2000). This led to challenge on the 
v; o= -or-u1bm bm -mbl-Ѵv Ő77ķ ƐƖƖѵ-ķ ƐƖƖѵ0ő |_;m |o - 0-m
om b|v v; bm uor; bm ƐƖƖƕĺo;;uķ |_;u;-vl-fou 1om|uo-
versy. Notwithstanding the fact that avoparcin was not licensed for 
=oo7Ŋruo71bm]-mbl-Ѵvbm|_;&"ķ(!-v-||_bv|bl;-v;ubov
1Ѵbmb1-Ѵbvv;=ou_l-ml;7b1bm;bm|_;&"ķ0|r-u-7ob1-ѴѴmo|
in Europe. The apparent paradox reflects the difference between 
ubvh -m7 _--u7ĺ m |_;&"ķ |_; ubvh o=(! =ou _ovrb|-Ѵb;7 r--
tients was explained by the over-consumption of glycopeptides 
and other AMDs in hospitalized patients. In Europe, where the re-
vbv|-m1; bm 1Ѵbmb1-Ѵ 0-1|;ub--v 1omvb7;u-0Ѵ Ѵo;u |_-m bm&"ķ
it was primarily a hazard for the general population, arising from 
use of avoparcin as a growth promotor. This led some to challenge 
any “evangelical call for action,” as there was no robust evidence to 
support the spread of AMR gram-positive bacteria from livestock 
|o_l-mvŐ1-uķ-v;;ѴѴķu;;l-mķubbvķşoovv;mvķƑƏƏƏőĺ
Many calls were made for a total ban on the use of all AMDs as 
]uo|_ruolo|;uvbm-mbl-ѴvŐ-m7;mo]--u7ş"|o00;ubm]_ķƐƖƖѵķ
ƐƖƖƖĸ77ķƐƖƖѵ0őĺmƐƖѶѵķ";7;mrbom;;u;7ruo_b0b|bomo=bm-
corporation of antibiotics in animal feeding-stuffs, including the use 
o= -ѴѴ -m|b0bo|b1Ŋ1om|-bmbm] -77b|b;vĺ ";7;m u;|-bm;7 |_bv u;v|ub1-




used for growth promotion in 1999. An EU-wide ban was placed 
on animal feed additives containing antibiotics in the EU and this 
0;1-l;;==;1|b; =uolƐ -m-uƑƏƏѵ ŐmomlovķƑƏƏƔőĺuol
this date, food derived from livestock using AMD for growth pro-
motion could not be marketed or used. In parallel, the European 
m|b0bo|b1!;vbv|-m1;"u;bѴѴ-m1;"v|;lŐ!""ő-v;v|-0Ѵbv_;7
bmƐƖƖѶĺ"ol;-|_ouv1_-ѴѴ;m];7|_;0-mŐ_bѴѴbrvķƑƏƏƕő0||_;ķ
in turn, were challenged on grounds of misinterpretation of data 
Ő-ll;ul;|-ѴĺķƑƏƏƕőĺ
It was predicted that the ban on the use of antibiotics as growth 
promoters in animals would be associated with an increased inci-
dence of food-borne diseases in humans and more frequent use 
of antibiotics for therapeutic purposes in animals (Casewell, Friis, 
-u1oķ 1ѴѴbmķ ş _bѴѴbrvķ ƑƏƏƒőĺ o;;uķ -m ;rb7;lboѴo]b1-Ѵ
v|7Őu-;ķ-Ѵ7_v7-Ѵķuv;ķ-uuķşѴ-|Ѵ-m7vloķƑƏƏƓő=om7
no compensatory increase in the level of therapeutic use of AMDs 
ŐumoѴ7ķ-vvm;uķb];uķş,-_Ѵ;mķƑƏƏƓőĺou;o;uķblruo;l;m|
in productivity following the ban indicated no long-term impact 
om vbm; ruo71|bb| Ő-u;v|urķ ;mv;mķ l0ou]ķ -1o0v;mķ ş
);];m;uķƑƏƐƏĸ;mv;mş-;vķƑƏƐƓőĺ
ou|_;&mb|;7"|-|;vķ-b7;Ѵbm;=oum7v|uķbvv;7bmƑƏƐƑ0
the Center for Veterinary Medicine (CVM) of the FDA (Anonymous, 
ƑƏƐƖ1ő u;1oll;m7;7 ľ$_; 7b1bov &v; o=;7b1-ѴѴ lrou|-m|
Antimicrobial Drugs in Food-Producing Animals,” that is sanctioning 
use for the prevention, control and treatment of infections in animals 
but not for growth promotion, increased performance and improved 
=oo71om;uvbom;==b1b;m1ĺ77b|bom-ѴѴķ|_;b7;Ѵbm;u;v|ub1|v|_;
use in animal agriculture of some AMDs of critical importance (e.g. 
third-generation cephalosporins). These drugs are now reserved for 
use in humans.
After a transitional period, based on the voluntary decision of 
companies to cease selling AMDs for this use, a new FDA regulation, 
;==;1|b;=uolƐ-m-uƑƏƐƕķ0-mm;7|_;v;bm&"o=-m|b0bo|b1v
as feed supplements for livestock and poultry. It also prohibits over-
the-counter sale to farmers of AMDs medically important for hu-
mans, and farmers are required to obtain prescriptions for all AMDs 
Ő	uobѴѴ-u7ķƑƏƐѶőĺmƑƏƐƖķ_bm-7;1b7;7|o0-m|_;v;o=	v-v
growth promoters, which will take effect in 2020. Currently, China is 
more concerned with domestic policy and resource competition than 
b|_-77u;vvbm]|_;;bv|;m|b-Ѵ_;-Ѵ|_|_u;-|=uol!Ő$_ol-vşoķ
2020). The concern is that implementation of welcome decisions might 
v==;u|_;v-l;=-|;-v|_ov;o=|_;"-mmu;rou|u;1oll;m7-|bomvĺ
ѶՊ|Պ ՊՍ LEES Et aL.
ƒĺƓՊ|Պ$_;1uu;m|v;o=-m|blb1uo0b-Ѵv-v]uo|_
ruolo|;uvbmѴoŊ-m7lb77Ѵ;Ŋbm1ol;1om|ub;v
Using Bayesian statistical models, which take account of livestock 
densities and projections of demand for meat products and cur-
rent estimates of AMD consumption in high-income countries, the 
global trend in AMD use in food animals was predicted to increase 
significantly (Van Boeckel et al., 2015). It was estimated that, be-
tween 2010 and 2030, overall consumption of AMDs would in-
1u;-v;ķb=mo-1|bom-v|-h;mķ0ѵƕѷĺ$_bvbvѴ-u];Ѵ-||ub0|-0Ѵ;
to changing production practices in middle-income countries, 
where extensive farming systems will be replaced by intensive 
farming operations that routinely use AMDs in sub-therapeutic 
doses (Van Boeckel et al., 2015). To mitigate potentially conse-
quential ecological disasters, several scenarios to reduce AMD 
consumption were simulated. One of the most efficient would be 
worldwide promotion of low-animal–protein diets, that is to dras-
|b1-ѴѴu;71;l;-|1omvlr|bom0_l-mvbm);v|;um1om|ub;v
and to encourage those countries having currently a low meat con-
sumption per capita to adopt a plant-based diet, in preference to 
animal-based food. As the world’s largest consumer of veterinary 
AMDs, both in relative (per animal body weight) and in absolute 





m |_; 7;1-7; ƐƖƔƏŋƐƖѵƏķ |_; ru;7olbm-m| |_;u-r;|b1 bm7b1--
tion for AMDs in food-producing animals was mastitis in dairy 
cattle. This arose because mastitis is an infectious condition of 
]Ѵo0-Ѵ u;-1_ĺ=|;uƐƖѵƏķl-mr0Ѵb1-|bomvom77;u1om7b|bomv
continued to dominate the cattle infectious disease literature, 
with research reports on the pathophysiology of mastitis, as well 
as many clinical trials on AMD-containing products administered 
by intramammary infusion. Mastitis was and is a condition at the 
interface of veterinary medicine and animal husbandry. The earli-
est mastitis control programmes and treatment recommendations 
;u; blrѴ;l;m|;7 bm |_; ƐƖѵƏvĺ-v|b|bv ru;;m|bom -v m;;u
regarded as the sole domain of veterinarians (LeBlanc, Lissemore, 
;Ѵ|omķ	==b;Ѵ7ķş;vѴb;ķƑƏƏѵőĺ!-|_;uķ |_;|_;u-r;|b1v;vo=
AMDs, from initial diagnosis, to selection of drug of choice, to ad-
ministration strategy have involved integrated decision-making 
management options, as outlined in national Mastitis Control 
Programmes in many countries. Even systemic therapy is feasible 
in sub-clinical conditions, through availability of efficacious AMDs 
such as ceftiofur, having a milk discard time of 0 to 2 days, depend-
bm]om|_;1om|uŐ-v1_;ş!o00ķƑƏƏƒőĺ
)_;u;-v 1Ѵbmb1-Ѵ l-v|b|bv bv u;-7bѴ 7;|;1|;7 -m7 |u;-|;7ķ |_bv
is not the case for the most prevalent form, sub-clinical mastitis. 
)_bѴv| vb]mvo= |_; v0Ŋ1Ѵbmb1-Ѵ 1om7b|bom-u;mo| u;-7bѴ-rr-u;m|
to the veterinarian, detection by the farmer becomes apparent 
through lower yield and altered quality of milk, together with his 
acute awareness of economic losses. Progressive lowering of regu-
Ѵ-|ouѴblb|v=ou0ѴhlbѴhvol-|b11;ѴѴ1om|vŐ"ő;m1ou-];7|_;
use of AMDs by farmers. This led to promotion of blanket strate-
gic AMD therapy at drying-off to cure ongoing chronic conditions 
-m7ru;;m|=|u;bm=;1|bom-|1-Ѵbm]Ő	o77ķ);v|]-u|_ķ;-;ķş
bm]bѴѴķƐƖѵƖőĺoul-m;-uvķb|-v1Ѵ-bl;7|_-||_;Ѵo1-Ѵ	
use for mastitis control in dairy cows had minimal impact on the 
;l;u];m1; o= ! ŐѴb;uķubm7-ķ ş --u-oķ ƑƏƐƐőĺ o;;uķ
this limited view failed to recognize the consequences of such rou-
tine practices as the re-cycling of wasted and unsaleable milk as 
=;;7=ou1-Ѵ;vŐum|omķ	m1-mķoѴ7_-lķ"moķşom;vķƑƏƐƑĸ
Duse et al., 2013). This practice is responsible for the emergence 
of AMR in the gastrointestinal tract (g.i.t.) microbiota of preweaned 
1-Ѵ;vŐ;u;bu-;|-ѴĺķƑƏƐѶőĺ"ol;u;71|bomo=	v;=oul-v|b|bv
therapy is clearly now appropriate, in conjunction with implemen-
tation of alternative approaches. These include nonantimicrobial 
therapy with new compounds, such as those that are assumed to 
improve the immune status of the udder at the time of calving and 
|_;r;ubŊr-u|lr;ubo7 Ő(-m"1_m7;Ѵķ-uub;uķo]-7o-v1o||bmbķ
ş ;Ѵ-m1ķ ƑƏƐѶő -m7 v;Ѵ;1|b; 7u 1o |u;-|l;m|v Őuक़lh;u ş
;bl0-1_ķƑƏƐƕőĺ
From a pharmacological perspective, it is with the treatment of 
mastitis that clinical veterinary pharmacology really began to be 
the subject of focused research. In a series of classical papers in 
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internationally for his research on bovine mastitis. He 
conducted pioneering researches in several aspects, embracing 
pharmacokinetics, residues and clinical efficacy of intramammary 
infusions of antimicrobial drugs





b;;7 0omv|-0Ѵ; -m7oubm Őomv|-0Ѵ;şoubmķ ƑƏƏƒő -m7
also challenged. A classical overview of advances affecting the 
health and welfare of dairy cows has been presented (Barkema 
et al., 2015). Automated milking systems and the adoption of new 
technologies, together with possibilities of using milk for disease 
diagnostics and monitoring, will ineluctably impact on mastitis 
1om|uoѴ -m7 |_; rѴ-1; o= 	v bm |_;u-r Ő-1o0v ş "b;]=ou7ķ
2012).
The early unique approach to mastitis, evaluating its causes and 
management, was not matched by comparable research programmes 
on the pathophysiology and therapeutic innovations for other major 




Contributions made by several pharmacologists (notably 
!-vlvv;mķ(-mb;u|ķov-m7,bő-u;o|Ѵbm;7 bm";1|bomƑ
of this review. It was in the mid- to late-1990s that other pharma-
cologists became involved in quantifying AMD concentrations in a 




These researchers derived PK parameters and variables and ap-
plied them in PK/PD integration and modelling methods. The 
correlated PK and PD data were used to characterize types of 
bacterial kill (concentration-dependent, time-dependent or co-
dependent) and to predict dose schedules for a given Probability 
of Target Attainment (PTA) also termed Target Attainment Rate 
(TAR) (see review by Toutain et al. in this issue). As early as 2002, it 
was advocated in the veterinary field that dosage regimens should 
be optimized using the PK/PD paradigm, in preference to the clas-
vb1-Ѵ7ov;ŋ;==;1|u;Ѵ-|bomv_brŐѴb-0-7bş;;vķƑƏƏƑĸ$o|-bmķ7;Ѵ
-v|bѴѴoķşovt;|Ŋ࣐ѴoķƑƏƏƑőĺ
In earlier decades, the focus of pharmacologists had been on 
factors (species, breed, age, sex, disease, feeding schedule, dose, 
route of administration etc.) influencing variability of AMD PK pro-
=bѴ;vĺ=mo|;;u;|_;1Ѵ-vvb1-Ѵv|7b;vo="|o;-m7!-vlvv;mom
vѴ=om-lb7;v Őv;;";1|bomƐom vѴ=om-lb7;vő -m7,b =oulbѴh
ruo=bѴ;v -m7l-v|b|bv Őv;; ";1|bom ƓĺƐőĺ -u|b1Ѵ-u mo|; -Ѵvo v_oѴ7
0;l-7;o=|_;uoѴ;vo=	;vlom7ĺ-]]o|-m7Ѵo7ĺ	-b;vĺm
|_;ƐƖƕƏvķ-]]o| 1oŊ-|_ou;7b|_	-bvo= ѴѴbmobv&mb;uvb| -|
Urbana a series of papers on the comparative PK of several drugs, 
bm1Ѵ7bm] 1_Ѵou-lr_;mb1oѴ Ő	-bvķ ;==ķ -]]o|ķ ş o;uvķ ƐƖƕƑőķ
-m7ombm|;uŊvr;1b;v7b==;u;m1;vbmruo|;bm0bm7bm]Ő-]]o|ş	-bvķ
ƐƖƕƒĸ-]]o|ķ	-bvķş;==ķƐƖƕƑőĺ-]]o|Őb]u;Ɩő-|_ou;7|_;
first book dedicated to veterinary clinical pharmacology (Principles 
of Drug Disposition in Domestic Animals: the Basis of Veterinary Clinical 
Pharmacologyĸ-]]o|ķƐƖƕƕőĺ
This text retained its status as the most influential for our dis-
cipline for several decades. Baggot also wrote the first review on 
the comparative disposition of AMDs in healthy and diseased an-
bl-Ѵv Ő-]]o|ķ ƐƖѶƏőĺ)b|_ o_m ĺ u;v1o||ķ -]]o|-v |_; =buv|
editor of the classical book “Antimicrobial Therapy in Veterinary 
;7b1bm;ķĿ Őu;v1o||ş-]]o|ķƐƖѶѶőĺ lrou|-m| u;1;m| u;b;v bm
this field on the effect of sex, heritable traits, age, body composition, 
circadian rhythms and disease are those of Martinez and Modric 
Ő-u|bm;şo7ub1ķƑƏƐƏĸo7ub1ş-u|bm;ķƑƏƐƐőĺ
m|_;ƐƖѵƏvķ(-mb;u|o=&|u;1_|&mb;uvb| Őb]u;Ɠől-7;






influence of fever on drug disposition (van Miert, 1990). Van Miert 
pioneered the introduction into veterinary medicine of hepato-
cyte cultures to investigate AMD metabolism (Mengelers, Kleter, 
oo];m0oolķ br;uķ ş (-m b;u|ķ ƐƖƖƕĸ )b|h-lrķ bfl;bf;uķ
omv_o;uķ ş (-mb;u|ķ ƐƖƖƔőĺ ou; u;1;m|Ѵķ -rb1_ _-v rb-
oneered tissue PK distribution studies of AMDs (see review by 
Toutain et al, in this issue) and played a major role in interfacing 
b|_1Ѵbmb1b-mvŐv;;";1|bomƓĺƓőĺ
 &! ƖՊ	;vlom7-]]o|ŐƐƖƓƏŋƑƏƐѵő-|_ou;7l-m
articles and reviews, including some classical papers, including 
“Distribution of anti-microbial agents in normal and diseased 
-mbl-ѴvĿŐ-]]o|ķƐƖѶƏőĺ;-Ѵvo-|_ou;7|_;=buv|0ooh7;7b1-|;7
to veterinary clinical pharmacology (Principles of Drug Disposition 
in Domestic Animals: the Basis of Veterinary Clinical Pharmacology 
Ő-]]o|ķƐƖƕƕőő
ƐƏՊ|Պ ՊՍ LEES Et aL.
Most recently, PK/PD modelling with Monte Carlo simulation 
has enabled pharmacologists to establish or confirm rational dos-
age regimens. A recent example is tulathromycin (Toutain, Potter, 
;|-ѴĺķƑƏƐƕőŐv;;-Ѵvo|_;u;b;omņ	0$o|-bm;|-Ѵbm|_bv
issue). Also contributing to these pioneering advances in pharma-
1oѴo]-u;rorѴ-|boml;|_o7vŐom;|-ѴĺķƑƏƐѶĸbmķ;_ubm]ķ




MICs required to establish a clinical break point for antimicrobial 
v;mvb|bb||;v|bm]Ő"$ő0(-v|ņ"Ő-rb1_ķƑƏƐƓő-m7(;|"$ķ
- v0Ŋ1ollb||;; o= &"$ Ő$o|-bmķ ovt;|Ŋ࣐Ѵoķ ;| -Ѵĺķ
ƑƏƐƕőĺo;Ѵ -rruo-1_;v |o |_;7;vb]mo=7ov; v1_;7Ѵ;v_b1_
optimize bacteriological cure and minimize opportunities for the 
emergence of resistance are promoted (for a recent review see 
-u7-0-vvbķrѴ;ķѴv;mķ$o|-bmķş);;v;ķƑƏƐѶőĺ mvbѴb1o-r-
proaches, as veterinary alternatives to in vivo dose fractionation 
studies (traditionally conducted using rodent models) to identify 
the best PK/PD index predictive of AMD efficacy, have recently 
0;;mbm|uo71;7Ő;ѴѴb]-m7ķ;;vķ"b7_ķş$o|-bmķƑƏƐƖőĺ$_;uoѴ;
of biofilms, notably in recurrent mastitis infections was investi-
]-|;7Ő;Ѵ1_bouķbmhŊu;ll;Ѵvķş--v|u-ķƑƏƏƕő-m7u;b;;7bm
ƑƏƏѵŐ;Ѵ1_bouķ(--uh-lrķşbmhŊu;ll;ѴvķƑƏƏѵőĺ
)_bѴv| |_; v1b;m|b=b1 0-vbv o= ;|;ubm-u |_;u-r;|b1v 0;]-m |o
emerge in the nineteenth century, the transition from Materia Medica 
to pharmacology occurred as late as the 1950s with publication of 
the classical textbook Veterinary Pharmacology and Therapeutics in 
ƐƖƔƓķ-|_ou;70ĺ;;uom;vĺ$_bvmagnum opus continues to 
be the veterinary pharmacologists’ bible, now in its 10th edition 
ŐƑƏƐƕő m7;u |_; ;7b|ouv_br o= !bb;u; -m7 -rb1_ĺ | bm1Ѵ7;v |_;
most comprehensive pharmacological review available on AMDs 
in use, on a class-by-class basis. A milestone development for the 
veterinary pharmacology community was the launching of an in-
|;um-|bom-Ѵ foum-Ѵ bmƐƖƕѶķThe Journal of Veterinary Pharmacology 
and Therapeutics,m7;u|_;;7b|ouv_bro=_-uѴ;v"_ou|-m7m7u;
Yoxall.
Finally, the bi-annual “International Conference on Antimicrobial 
Agents in Veterinary Medicine” (AAVM) inaugurated, nurtured and 
1_-bu;70"|;=-m"o0-1h_-vruob7;7-mbm|;um-|bom-Ѵ=oulķ_;u;
microbiologists, pharmacologists and other specialists meet to dis-
seminate the latest knowledge on AMD actions and usage. From its 
first inception in 2000 in Helsinki to the 9th Conference held in Rome 
bmƑƏƐѶķb|_-vruob7;7-rѴ-|=oul=ou7;0-|;-1uovv-u-m];o=7bv1b-
plines between scientists based in academia, regulatory authorities, 
industry and veterinary clinical practice.
ƓĺƒՊ|ՊѴbmb1b-mvĽuoѴ;vĹ7u];==b1-1bm=oo7
ruo71bm]-mbl-Ѵv
v 7bv1vv;7 bm ";1|bom ƓĺƐķ l-v|b|bv |u;-|l;m| rbom;;u;7 1Ѵbmb1-Ѵ
research on the use of AMDs in veterinary medicine. It was only 
later that bovine respiratory disease (BRD), historically termed 
pneumonia or shipping fever, was investigated by clinicians. In the 
ƐƖѵƔķ$_bu77b|bomo=|_;v|-m7-u7u;=;u;m1;|;|0oohľ(;|;ubm-u
_-ul-1oѴo] -m7$_;u-r;|b1vĿ Ő;;u om;vķ ƐƖѵƔőķ |_; 1_;lo-
therapy chapter reported that there was no prophylactic medication 
to protect cattle against respiratory infection, although tranquillisers 
_-70;;m1Ѵ-bl;7|oru;;m|v_brrbm]=;;uŐ0;uķƐƖѵƔőĺ=-1|ou
accounting for the lag between AMD treatment of mastitis and that 
of lung conditions is that dairy cattle are under daily scrutiny of the 
=-ul;u-|lbѴhbm]Ő0;uķƐƖѵƔőĺm7;1ouv;ķ|_;v;o=	v|o
treat BRD, the most economically important disease of feed-lot ani-
l-Ѵvķ-vu;Ѵ-|;7|o|_;u-rb77;;Ѵorl;m|o==;;7ŊѴo|vbm|_;ƐƖѵƏvķ
encompassing hybrid grain and irrigation techniques (O’Connor et al., 
ƑƏƐѵőĺ
For the treatment of respiratory diseases, the tetracycline group 
(oxytetracycline, chlortetracycline, doxycycline…) remains in wide-










Tilmicosin Macrolide Elanco Micotil 1990
Florfenicol Phenicol "1_;ubm]ŊѴo]_ Nuflor 1990




Marbofloxacin Fluoroquinolone Vetoquinol Marbocyl 1995
Tulathromycin Macrolide Pfizer Draxxin 2003
-lb|_uol1bm Macrolide Merial ,-1|u-m ƑƏƏѶ
Tildipirosin Macrolide Intervet ,ru;o 2011
a7-r|;7-m7r7-|;7=uol"_uo1hŐƑƏƏƓőĺ
$ ƐՊ";t;m|b-Ѵbm|uo71|bomo=
AMDs for respiratory disease in cattlea
ՊՍ Պ |ՊƐƐLEES Et aL.
are low cost, convenience of oral administration and availability in 
long-acting formulations, enabling single-dose therapy. However, 
several negative issues were revealed for these products, including 
Ѵo-m7;uu-|b1ou-Ѵ0bo--bѴ-0bѴb|ķ |rb1-ѴѴo=ƐƏѷou Ѵ;vv bmrb]v
Őb||Ѵ;ķu-00ķ)oo7-u7ķuombm]ķşbѴѴl-mŊ-1o0;ķƑƏƐƖőķ -m7
for systemic administration, of a poor local tolerance. The latter with 
a significant tissue irritation is an animal welfare issue and also a 
possible human safety concern due to residues at the injection site. 
Nouws expressed early concerns on the advantage/risk balance of 
|_;v; Ѵom]Ŋ-1|bm] o|;|u-11Ѵbm; =oulѴ-|bomv Őovķ ƐƖѶƓőĺ v
for all antimicrobials, the development of resistance and efficacy 
issues were increasingly reported for tetracyclines. This led to the 
bm|uo71|bomķ1oll;m1bm]bm|_;Ѵ-|;ƐƖѶƏvķo=|_;ľlo7;umĿu-m];
o=	vķmo|-0Ѵ;muo=Ѵo-1bmbmƐƖѶƕŐ$-0Ѵ;Ɛőĺ
The relative efficacy of these AMDs has recently been assessed 
using a mixed-treatment comparison meta-analysis and Ranking 
ou;v|rѴo|v Őŝommou;| -Ѵĺķ ƑƏƐѵőķ v]];v|bm] |_-| |_;_bv|oub1-Ѵ
treatment with oxytetracycline (the main reference drug for sev-
eral decades) does not differ significantly from nonactive control 
therapy.
One Health concerns, arising from the contribution of veteri-
nary medicine to global AMR issues, have triggered new regulatory 
guidance, which includes restriction on the prophylactic use of 
	v Őv;;";1|bomѵőĺoķ-mo0f;1|b; =ou 1Ѵbmb1b-mv bmoѴ;7 bm
food-producing animal medicine should be to re-visit the practice 
of metaphylaxis (sensu stricto of very early AMD treatment). As a 
therapeutic option, metaphylaxis is soundly based, given the greater 
efficacy of AMDs when administered during the prepatent period 
o=-mbm=;1|bomŐ;uu-mķ$o|-bmķşovt;|Ŋ࣐ѴoķƑƏƐƐĸ(-vv;uķ
-1uobķ $o|-bmķ ovt;|Ŋ;Ѵoķ ş ;uu-mķ ƑƏƐƕĸ (-vv;u ;| -Ѵĺķ
ƑƏƐƓőĺ$_;1_-ѴѴ;m];ķ_o;;uķ bv|ou;rѴ-1;ķ-v-l-m-];l;m|or-
tion, the mass medication with which metaphylaxis is almost always 
blrѴ;l;m|;7Ő-r|bv|;şv]--u7ķƑƏƐƕőķ0lou;v;Ѵ;1|b;|u;-|-
ments, that is by application of precision medicine. Rapid progress 
in precision medicine is envisaged and, with the technical feasibility 
of individual animal treatment, monitoring disease onset will be-
1ol;ru-1|b1-0Ѵ;ķ ;;m -| =Ѵo1h -m7 _;u7 Ѵ;;Ѵv Őovt;|Ŋ࣐Ѵoķ
ƑƏƐѶĸ_;ulb;ķ$o|-bmķѴ-u1_ķovt;|Ŋ࣐Ѵoķşvvb࣐ķƑƏƐƕőĺ
The components of evolving precision medicine are as follows: the 
1om71| o= bmŊ7;r|_ u;v;-u1_;v om 7b-]movbv Ő-1hvomķ -uv|;mvķ
$;7;v1_bķşbm1_-hķƑƏƐѵőĸ-m7|_;v;o=7b-]mov|b1|ooѴvb|_v;m-
vouv Ő!||;mķ (;Ѵ|_bvķ "|;;m;;Ѵ7ķ şo];;;mķ ƑƏƐƒő |o ruob7;
selective clinical treatments as an alternative to mass medication.
ƓĺƓՊ|ՊѴbmb1b-mvĽuoѴ;vĹ7u];==b1-1=ou
1olr-mbom-mbl-Ѵv
m |_; ƐƖƔƏvŋƐƖѵƏvķ |_;u; ;u; u;Ѵ-|b;Ѵ =; 1Ѵbmb1b-mŊ-|_ou;7Ľ
papers addressing small animal infectious disease. The consequence 
was failure to document important issues requiring clinical exper-
tise, including decisions on: when to commence; how long to main-
tain treatment and what dose to select. Nevertheless, from the 
early 1950s, the PK basis for rational dosing of penicillin was known; 
"1_;b7ŐƐƖƔƐőu;rou|;7|_-|r;mb1bѴѴbmķ0;bm];uu-rb7Ѵ;Ѵblbm-|;7
by the kidney, made necessary the selection of an appropriate salt 
ou=oulѴ-|bomĺ	-b7)-|vomo="7m;&mb;uvb|-vom;o=|_;
first veterinary pharmacologists to document the PK of AMDs in 
7o]v-m71-|v Ő)-|vomķƐƖƕƑķƐƖƖƐőĺ11ou7bm] |o"_uo1hķ b|-v
only in the 1990s that the research focus of animal health companies 
shifted from products for use in food animals to products targeting 
1olr-mbom-mbl-ѴvŐ"_uo1hķƑƏƏƓőĺ
In developing AMDs for companion animal diseases, clinical trials 
were pivotal. Drug companies largely copied and pasted the drugs 
and dosage regimens established in human medicine onto compan-
ion animals. This explains why some historically set dosage regimens 
have recently been debated and updated. For example, amoxicil-
Ѵbmb|_ 1Ѵ-Ѵ-mb1 -1b7-vl-uh;|;7 bm |_; Ѵ-|;ƐƖƕƏv bm 1-|v 0
Beecham Laboratories as Clamoxyl®. In a clinical trial conducted by 
|_;vromvoubmƑƑƓ1-|vķb|-vu;rou|;7|_-|ƖƓѷ;1;ѴѴ;m|Ŋ|oŊ]oo7
results were obtained with a fixed oral dose of 50mg administered 
once or twice daily. A second trial employing 193 cats was con-
ducted to determine the frequency of dosage of this tablet. The 
results indicated that the efficacy of 50-mg amoxicillin given once 
daily was equal to that of two 50-mg doses per day for a range of 
1om7b|bomvŐu;vrbu-|ouķubm-uķvhbmĻőŐ;;=;ķƐƖƕѶőĺ$_bvu;]bl;mbv
still marketed but consensus guidelines now indicate for amoxicillin 
a dosage per kg body weight and not a per animal dose. Moreover, 
dosage regimens vary for differing conditions; 22 mg/kg twice daily 
=ouu;vrbu-|ou1om7b|bomvŐ-rrbm;|-ѴĺķƑƏƐƕőķƐƐŋƐƔl]ņh];;u
Ѷ_=ouubm-u|u-1|bm=;1|bomvŐ);;v;;|-ѴĺķƑƏƐƐő-m7ƐƑŋƑƔl]ņh]
in association with clavulanic acid for treatment of superficial bacte-
ub-Ѵ=oѴѴb1Ѵb|bvbm|_;7o]ŐbѴѴb;u;|-ѴĺķƑƏƐƓőĺ
In earlier decades, clinical trial method and design were not 
well consolidated in veterinary medicine and, to support its prod-
1|ķ;;1_-l-0ou-|oub;vr0Ѵbv_;7-ľ1Ѵbmb1-Ѵ|ub-ѴĿomѵƐƔ1-v;v
of dogs and cats from which it was stated “Those taking part were 
asked to use amoxicillin in the treatment of all conditions that they 
considered required an antibiotic and to report their results in 
terms of success or failure according to criteria laid down” (Francis, 
-uv_-ѴѴķş$um;uķƐƖƕѶőĺ
In the present century, veterinary pharmacology and therapeu-
tics have become a more active and sophisticated field. Now many 
guidelines for the rational use of AMDs and dose design (Lappin 
;| -Ѵĺķ ƑƏƐƕĸ);;v;;| -Ѵĺķ ƑƏƐƔķƑƏƐƖőĸ =Ѵovo=r0Ѵb1-|bomv7;7-
b1-|;7 |o vr;1b=b1 	 1Ѵ-vv;vķ =ou ;-lrѴ; tbmoѴom;v Ő)-Ѵh;uķ
2000) or to named species, both dogs (Papich, 2012, 2013) and cats 
ŐѴ0-u;ѴѴovş-m7ombķƑƏƏƖőķ_-;v;|m;v|-m7-u7vĺ
ƓĺƔՊ|Պm7v|uĽvuoѴ;bm7;;Ѵorbm]m;7u]v
The pharmaceutical industry has been a major and beneficial inno-
vative force in the discovery, development and marketing of AMDs, 
formulated in a wide range of products for the seven major species 
of veterinary interest.
ƐƑՊ|Պ ՊՍ LEES Et aL.
Many AMDs developed for veterinary use arose secondarily to 
their introduction into human medicine, including for example the 
early, narrow spectrum penicillins, sulfonamides and amoxicillin 
Ő-Ѵl;uķv;ѴѴķ	oub1hķş+;ol-mķƐƖƕѵőĺ$_; ľlo7;um;u-Ŀo=
veterinary antimicrobial therapy was initiated with the regulatory 
approval of the first veterinary fluoroquinolone (enrofloxacin) in 
ƐƖѶƕķ-m7|_;=buv||_bu7Ŋ];m;u-|bom1;r_-ѴovroubmŐ1;=|bo=uőbmƐƖѶѶ
(Table 1). These two AMD classes are currently the most challenged 
in terms of public health, emphasizing that veterinary medicine must 
constantly review its AMD armamentarium, if it is to meet public 
health expectations in the 21st century and optimize outcome in 
treating animal diseases. Therefore, there is now a need to develop 
new compounds with minimal impact on g.i.t. flora and on environ-
mental bacterial ecosystems (Toutain, Ferran, Bousquet-Melou, 
;ѴѴb]-m7ķş;;vķƑƏƐѵőĺ
Many of the AMDs used in veterinary, but not in human, med-
icine were drugs that did not proceed to licensing for human use 
for safety or other reasons. Others are second-in-class drugs or 
drugs not showing sufficient promise at some stage of development. 
Veterinary licensing thus gave some “payback” to companies on re-
search development costs. For example, tiamulin was considered too 
toxic for human use. Enrofloxacin is an example of a second-in-class 
veterinary quinolone. In several species, it is a pro-drug of ciproflox-
acin and both parent compound and metabolite account for the anti-
microbial activity. The same may also be true for pradofloxacin (Lees, 
2013) versus moxifloxacin.
A few drugs in the veterinary AMD armamentarium were inno-
vatory. For example, the replacement of chloramphenicol by flor-
fenicol was dictated by the need to resolve a tissue residue issue in 
food-producing species, as reviewed by Page (Page, 1991). A sec-
ond example is those macrolides of the azalide sub-group, such as 
|Ѵ-|_uol1bmŐuvb1;|-ѴĺķƑƏƐѶĸ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for sole veterinary use. The therapeutic advantage of azalides is 
their long elimination half-life, single-dose therapy providing a long 
duration of action. Following the successful introduction of tulath-
romycin, pharmaceutical companies were motivated to introduce 
o|_;u--Ѵb7;vķ]-lb|_uol1bm Ő-m]ķ;|;m7u;ķ-m-ķ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fits for sole veterinary use (Menge et al., 2012).
Few AMDs were developed specifically for veterinary medicine. 
An example of specific and extensive veterinary use is the iono-
phore group of coccidiostats; monensin has been used for the con-
|uoѴo=1o11b7bovbvbmroѴ|u=ou-Ѵlov|ƔƏ;-uvŐ_-rl-mķ;==;uvķ
ş)bѴѴb-lvķ ƑƏƐƏőĺ o;;uķ |_;u; bv mo 1Ѵ;-u v-m1|-u =ou ;|-
erinary AMDs. Tiamulin, a pleuromutilin derivative, was originally 
proposed for use in humans, but not developed for safety reasons. 
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regarded as a noncritical AMD for human medicine. However, 
pleuromutilins have been re-considered for use in human medicine 
Őo-hķ ƑƏƐƐőĺ m ;-lrѴ; bv Ѵ;=-lѴbm Ő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could not have been foreseen, but it is the case, that this veterinary 
AMD class has later become, in 2011, a human AMD class (Paukner 
ş!b;7ѴķƑƏƐƕőĺm|_;ruo1;vvķ-m7=uol|_;r;uvr;1|b;o=7;;Ѵor-
ment of resistance and impact on humans, pleuromutilin class drug 
usage in food-producing animals in the EU has been challenged (van 
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medicine, but it has now become a drug of last recourse in human 
medicine, for infections where the organism is resistant to a wide 
range of alternative drugs.
An example of therapeutic re-purposing, that is switching to an 
alternative or additional therapeutic use, is provided by the salic-
ylanilide class of anthelmintic drugs to treat infections caused by 
drug-resistant Staphylococcus aureus. Niclosamide and oxyclozanide 
were shown to possess strong activity in vivo and in vitro against 
!" Ő!-f-l|_b-_ ;| -Ѵĺķ ƑƏƐƔőĺ $_; u;Ŋrovb|bombm] o= ;|;ubm-u
drugs, such as rafoxanide and closantel, to provide a synergistic 
combination with colistin has been proposed to target multidrug-re-




Over many years, industry has made great strides in develop-
ing new modalities of AMD administration and new formulations. 
Terminologies describing dosage forms and release characteristics 
can be confusing; they have has been reviewed in a veterinary con-
|;|Ő-u|bm;ķbm7tbv|ķşo7ub1ķƑƏƐƏőĺ
Administration of AMDs in feed or drinking water required spe-
cific pharmaceutical development. This is essential to ensure stabil-
ity (e.g. at varying water pHs, in soft and hard waters), good mixing 
properties, animal acceptance and compatibility with feed. These 
factors have been reviewed for poultry (Vermeulen, 2002). For com-
panion animals, good appetence is required to ensure usage compli-
ance, especially for AMDs in cats, as exemplified by pradofloxacin 
Őb|v|;u;|-ѴĺķƑƏƏƕőĺ
The principal example of a specifically veterinary administration 
route is intramammary infusion of AMDs. An overview of factors 
affecting the disposition of intramammary preparations used to 
|u;-|0obm;l-v|b|bv-vr0Ѵbv_;7bm|_bvfoum-ѴŐ;_ubm]ş"lb|_ķ
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The development of long-acting (LA) formulations of AMDs has 
been especially beneficial to food-producing animals for parenteral 
(intramuscular or subcutaneous) dosing. Challenges and issues in 
7;;Ѵorbm]  =oulѴ-|bomv o= 	v _-; 0;;m u;b;;7 Ő"mķ
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how species-specific physiological variables are of importance for 
parenteral dosage (Martinez, 2011). A significant challenge for for-
mulators is to ensure AMD stability, not only over product shelf-life 
but also in animal tissues over several days postadministration. This 
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long-acting formulations, as for first and second cephalosporin gen-
eration drugs.
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In human medicine, the extensive use of generic products has 
been reported to increase the overall consumption of AMDs and 
associated with the emergence and spread of bacterial resistance 
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arising in veterinary medicine from the use of generics has been 
to encourage the use of older drug products, by the promotion of 
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clines, have low oral bioavailability, are marketed with historically 
derived dosage regimens e.g. doxycycline in pigs and are excreted 
into and spread widely within the environment. They provide a 
disincentive to the development of new and innovative products, 
required to meet the therapeutic needs of the veterinary com-
munity, whilst being consistent with One Health issues. The de-
velopment of novel eco-friendly agents, with minimal impact on 
commensal gut flora and biodegradability in the environment, is 
discouraged by the widespread use of generic drug products of 
some classes. These issues have been further discussed in con-




The global concerns on AMR, its incidence and spread, have stimu-
lated extensive searches for alternative means of disease control. 
Industry has responded by embarking on searches for credible, ef-
ficacious alternatives to or supplementary approaches to AMDs. 
These include probiotics, prebiotics, symbiotics, organic acids, en-
zymes, phytogenics, antimicrobial peptides, hyper-immune egg anti-
0o7b;vķ0-1|;ubor_-];vķ1Ѵ--m7l;|-ѴvŐ-77;ķblķ_ķşbѴѴ;_ofķ
ƑƏƐƕőķ Ő-]]ज-ķ -||-u;ѴѴbķ ş b--|bķ ƑƏƐƏőķ ŐŊ_-|-bmķ ƑƏƐƓőĺ
Exploring the potential contribution of bacteriophages to AMR 
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now succeed under the stimulus of new researches deriving from 
global pressures.
For bovine mastitis, vaccines have been proposed by some 
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can bring their own problems; they are not necessarily total pan-
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even be counter-productive, as exemplified by zinc and copper 
Ő+-7-mh_-_ķ!7bķş;um_o=|ķƑƏƐƓőĸbm1 bm1u;-v;7|_;ruorou-
tion of multi-resistant E. coli in vivo in piglets (Bednorz et al., 2013). 
A similar effect was observed with heavy metals in liquid pig ma-
mu;Őक़Ѵ;Ѵ;|-ѴĺķƑƏƐƑőĺ
Future innovations in AMD therapy will be based on the knowl-
edge base created by past successes, failures and misuses. For ex-
ample, the use of drug combinations was proposed to retard the 
;l;u];m1;o=u;vbv|-m1;Ő_-b|ķu-m;ķşbv_omķƑƏƏƕĸ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An early concern arising from AMD use was the issue of residues 
in milk, in consequence of their extensive use in mastitis therapy. 
;mb1bѴѴbm bv_b]_Ѵ-m|b];mb1-m7ķ bmƐƖƔѵķ b|-v;v|bl-|;70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sensitive during their lifetime to some food, drug, cosmetic or other 
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of milk samples in some surveys. In addition, penicillin was actually 
added (illegally) to milk to lower bacterial counts, a practice declared 
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1955 the FDA, under the Miller Amendment, approved the use of 
chlortetracycline in the processing of poultry, as a preservative, ex-
tending the shelf-life of meat and for fish preservation. According to 
Deartherage, the great promise of using antibiotics to prolong the 
useful life of perishable food items stimulated intensive work in both 
1-7;lb--m7 m7v|u Ő	;-|_;u-];ķƐƖƔƕőĺ mƐƖƔƔķ -| |_; bmb|--
tion of the FDA, a Medical Advisory panel concluded that antibi-
otics, including tetracycline, polymyxin and neomycin, all of which 
were contained in marketed mastitis products, did not pose public 
health concerns, even though they may be detected in marketed milk 
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tained antimicrobial residues as determined by the CHARM II assay 
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residues became a priority for public health reasons and in light 
of its impact on the dairy industry’s production of milk derivatives 
(cheese, yogurt…).
From the 1950s onwards, many publications appeared on both 
microbiological/biological and chemical analytical methods for de-
tection of residues in edible tissues. These publications quantified 
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rates of decline in AMD concentrations in edible tissues and 
also described control, rapid screening and confirmatory meth-
ods. Deriving from these researches, the concepts of “Method 
(-Ѵb7-|bomĿ -m7 ľoo7 -0ou-|ou u-1|b1;Ŀ 0;1-l; l-m7-|ou
for product licensing, introducing into veterinary medicine the 
concept of the “quality approach”. In addition, rapid advances in 
analytical methods were accompanied by a steady flow of publica-
tions describing improvements in drug extraction and quantifica-
tion and introducing such indices as Lower Limit of Quantification 
(LLOQ) of analytes.
The aminoglycoside group of AMDs illustrate the requirement 
for analytical methods which are selective, representative and have 
-rruorub-|; vĺ"ol;-lbmo]Ѵ1ovb7;v-u;7u]lb|u;vb|_
two or more components, each with its own disposition profile 
Ő"|;bml-mķvo_;uu-m;mķv_o-1_ķş"o0-1hķƑƏƏƑőĺ	bvrovb|bomruo-
files where 2 compartments could be identified can now be described 
by 3-compartment models, with improved analytical sensitivity. It is 
|_;v;1om7Ő0;|-őr_-v;o=-rruobl-|;ѴƑŋƓ_uķbm-ѴѴvr;1b;vķ|_-|
is clinically relevant. However, for residues, it is the so-called very 
late-terminal (gamma) phase which accounts for the long withdrawal 




the final slow release of drug sequestered in tissues, particularly in 
the renal cortex. Accumulation and persistence at this renal site also 
accounts for aminoglycoside nephrotoxicity and withdrawal periods 
=ouhb7m;|bvv;ķ_b1_l-0;v;;u-Ѵ;;hvŐ;_ubm];|-ѴĺķƑƏƏƔőĺ
This persistency of aminoglycosides in tissues led to the progressive 
abandonment of aminoglycosides for use in food-producing animals.
The problems of penalties associated with residues of AMDs 
in milk and dairy products have given rise to several generations 
of rapid screening tests for monitoring noncompliant residues of 
AMDs in milk. One of the most popular was the Delvotest, devel-
or;7ƓƏ;-uv-]obm|_;;|_;uѴ-m7v-m7v|bѴѴv;7;|;mvb;ѴŐbom
et al., 2015). The several generations of the CHARM tests were de-
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For residues analyses, sophisticated, specific and sensitive meth-
ods are now used routinely, as well as multi-residue methods for si-
multaneous determination of different members of an AMD class 
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Residues of AMDs must conform to the general rules applying to 
drugs of all classes for setting Maximum Residues Limits (MRLs) (EU) 
ou |oѴ;u-m1;v Ő&mb|;7 "|-|;vő -m7 1-Ѵ1Ѵ-|bm] b|__oѴ7bm] r;ubo7v
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for monitoring residues, were important steps in building EU regula-
tions. The specific hazards of residues of AMDs in milk and other 
edible products are immunotoxicity (allergenicity), emergence of 
resistance in human g.i.t. microbiota and industrial hazards, through 
impacting on the manufacture of fermented products, such as cheese 
and yoghourt. In addition, there were drug-specific issues for some 
	vķ=ou;-lrѴ;1_Ѵou-lr_;mb1oѴŐv;;";1|bomƔĺƒőĺѴѴ;u];mb1b|
is not a significant issue for most AMDs, the main exception being 
benzylpenicillin. For a review of risks to humans of residues in edible 
tissues, see (Dayan, 1993).
For AMD residues' impact on the human intestinal flora, reg-
ulatory authorities require establishment of a microbiological 
Acceptable Daily Intake (ADI), if microbiologically active residues 
reach the human colon. At a conference held at the Royal College of 
Physicians in London on 2-3 December 1991 entitled “Antimicrobials 
bm (;|;ubm-u ;7b1bm;Ĺ 0Ѵb1 ;-Ѵ|_ -m7 oo7 (;|;ubm-u
Practices,” a session was devoted to evaluation of risk relating to res-
idues of veterinary AMDs. This provides the basis for evaluating res-
idues' risks for the g.i.t. flora (Boisseau, 1993; Corpet, 1993; Nord, 
1993) and promoting the concept of microbiological ADIs. At that 
time, Industry expressed some dissenting views and concluded that 
there was no scientific evidence, which might lead to the conclusion 
that residues have effects on human intestinal flora (Kidd, 1995). 
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(CVM) and Animal Health Institute (AHI) sponsored a symposium 
on the microbiological significance of drug residues in food. A tran-
script of symposium papers and ensuing discussion was published 
in a special issue of the journal, Veterinary and Human Toxicology 
(Teske, 1993). The consensus of the Congress was that the very low 
levels of AMDs, present as residues in food, will probably not pro-
duce deleterious effects on the human intestinal flora. The use of 
microbiological end points in the safety evaluation and elaboration 
of MRLs for veterinary drugs intended for use in food-producing 
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Kotarski, 2005). In due course, most regulatory agencies and inter-
national committees followed an harmonized process, as described 
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concentrations and persistence of AMDs of several classes, in-
cluding beta-lactams, aminoglycosides, tetracyclines, macrolides, 
chloramphenicol and sulfonamides in normal (healthy) and emer-
gency-slaughtered ruminants after parenteral and intramammary 
-7lbmbv|u-|bom Őovş,bķ ƐƖƕѶőĺ| |_-| |bl;ķ -m-Ѵ|b1-Ѵ -vv-
methods (microbiological) were relatively crude and MRLs were 
not established. Nevertheless, comparing depletion rates with the 
same PK model in healthy and emergency-slaughtered cattle, he 
1om1Ѵ7;7 |_-|ķ bm ou7;u |o ru;7b1|)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emergency-slaughtered ruminants, it was necessary to multiply by 
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animals.
Riviere promoted Physiologically Based Pharmacokinetic (PBPK) 
modelling, incorporating species- and chemical-specific parameters, 
to better predict the multiple factors impacting on residues, with 
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Riviere was an early promotor of the Food Animal Residue 
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a comprehensive computerized data-bank of invaluable regulatory 
and pharmacological information. FARAD was applied to mitigation 
of drug and chemical residue problems in food-producing animals 
and to facilitate trades between countries having varying standards 
Ő!bb;u;ķu-b]lbѴѴķş"m7Ѵo=ķƐƖѶѵőĺmƐƖƖѶķbmuor;ķm-7omo=
the University of Madrid reported extensively on both PK and regu-
Ѵ-|ou-vr;1|vo=	u;vb7;vbm=oo7vr;1b;vŐm-7ॕmş-u|d ةm;Ŋ
Larrañaga, 1999) especially in poultry (Anadón et al., 1995).
Regulations designed to manage residues risks were established 
in the framework concept of Risk Analysis (Food and Agriculture 
u]-mb-|bomo= |_;&mb|;7-|bomvş)ouѴ7;-Ѵ|_u]-mb-|bomķ
2009). This involved international cooperation between the princi-
r-Ѵou]-mb-|bomvŐķķ	Ļő1om1;um;7-m7-v_-ulo-
mb;7b|_bm|_;o7;Ѵbl;m|-ubvŐv;;";1|bomѵ-m7b]u;Ɣ=ou
relationships between these organizations).
ƔĺƒՊ|Պ$_;u;]Ѵ-|ouĽvuoѴ;Ĺ;-lrѴ;o=|_;0-mom
1_Ѵou-lr_;mb1oѴ-m7|_;7;;Ѵorl;m|o==Ѵou=;mb1oѴ
Chloramphenicol (CAP), formerly approved for use in cattle in the EU 
0|mo|bm|_;&"ķruob7;v-m;l0Ѵ;l-|b1;-lrѴ;o=r0Ѵb1_;-Ѵ|_
bvv;v-ubvbm] =uol;|;ubm-u7u] u;vb7;vĺ mƐƖѵƖķ-m bm1b7;m1;
of 1:30,000 patients treated with CAP suffered blood dyscrasias 
Ő)-ѴѴ;uv|;bmķom7b|ķ-vr;uķuomķşouubvomķƐƖѵƖĸ)-ѴѴ;uv|;bm
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the EU for use in food-producing animals (Commission Regulation 
ŐőƐƖƖƓő-m7bml-mo|_;u1om|ub;vķbm1Ѵ7bm]|_;&"ķ-m-7-ķ
v|u-Ѵb-ķ-r-m-m7_bm-ĺmƑƏƏƔķŐőŐv;;";1|bomѵő-|
b|vѵƑnd meeting concluded that determination of an ADI for human 
consumers of residues was not possible, because no threshold could 
be predicted for the aplastic anaemia. Because CAP is regarded as 
probably carcinogenic, the zero-tolerance approach was first en-
forced to comply with the use of the linear nonthreshold model (for 
a review of models used before the 1990s for residues assessment, 
v;;ş"b;Ѵh;mķƐƖƖƐőĺo;;uķruo]u;vvbm-m-Ѵ|b1-Ѵl;|_o7oѴ-
ogy, together with the unexpected and poorly understood ubiqui-
|ov ru;v;m1; o=  bm =oo7 ruo71|v Ő-m;h-lr ş -Ѵ-0u;v;ķ
ƑƏƏѵőķ-Ѵ0;b|-|;uѴoѴ;;Ѵvķ|o];|_;u-Ѵvob|_;b7;m1;o=|_;
natural occurrence of CAP in herbs and grasses (Berendsen et al., 
2010), account for nonfeasibility of the zero-tolerance requirement. 
In 2005, a Minimum Residues Performance Limit (MRPL) of 0.3 µg/
kg was assigned by the European Commission for analytical methods 
testing for CAP in products of animal origin. In consequence, the 
concept of a Toxicological Insignificant Exposure Level (TIEL) (Kroes 
;|-ѴĺķƑƏƏƓő-vblrѴb1b|Ѵ-11;r|;7ĺ$_;u;=ou;ķ-vmoѴom];u
u;]Ѵ-|;7-|;uoѴ;;Ѵ0|-||_;!ĺ)b|_|_bv7;1bvbomķ!v
have now been granted legal status in terms of explicit levels of toxi-
cological concern and have been applied to other substances includ-
ing nonveterinary residues.
The ban on CAP in food-producing species facilitated the intro-
duction florfenicol, a similar drug to CAP but lacking blood dyscrasia 
toxicity, for sole veterinary use. The in vitro activity of florfenicol 
-v =buv| u;rou|;7 bm ƐƖѶƑ Ő"uboroѴoķ -u7bm]ķ oѴ7l-mmķ ş
"lb|_ķƐƖѶƐőĺ$_;=buv|;|;ubm-ur0Ѵb1-|bom-rr;-u;7bm|_bvoum-Ѵ
bm ƐƖѶѵ Ő(-ul-ķ 7-lvķ o;uvķ o;uvķ ş -l;m7oѴ-ķ ƐƖѶѵőĺ |
-v 0-v;7 om 1oor;u-|bom 0;|;;m "1_;ubm] Ѵo]_ ourou-|bom
Őmo "	ő -m7 |_; 	;r-u|l;m| o= (;|;ubm-u _vboѴo] -m7
_-ul-1oѴo] o= _bo "|-|; &mb;uvb|ķ _;-7;7 0 $ol o;uvķ
om;o=|_;=-|_;uvo=;|;ubm-ur_-ul-1oѴo]bm|_;&mb|;7"|-|;v
(Figure 10). To date, more than 2,000 publications have been pub-
lished on this major veterinary AMD.
ƔĺƓՊ|Պ1o|ob1oѴo]Ĺ|_;uoѴ;vo=-m-Ѵv|vŐ1_;lbv|vőķ
lb1uo0boѴo]bv|v-m7;rb7;lboѴo]bv|v
Chemists’ contributions to the field of ecotoxicology, relating to 
the concept of One Health, are now highly significant. Matrices of 
interest are no longer confined to meat and milk but encompass 
 &! ƐƏՊThomas E. Powers (1925–2010) had many 
research interests in veterinary medicine. He specialized in 
the pharmacology of antimicrobial drugs especially florfenicol, 
developing an ethically acceptable tissue cage model to facilitate 
his studies on drug actions in vivo and ex vivo
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all components of the environment, air, water and soil. In the pre-
sent decade, ecotoxicology, underwritten by increasingly sensitive 
analytical methods, has become a major consideration, one major 
element of which comprises AMD use in veterinary medicine. Of 
increasing interest to chemists and others are as follows: the elimi-
nation of AMDs in urine from treated animals, driving the selection 
of resistant bacteria and of resistance genes in the environment 
Ő"00b-_ķ"_-_ķ;vv;uķ&ѴѴl-mķş-ѴѴķƑƏƐƑőĸ|_;ru;v;m1;o=	v
in soil (Thiele-Bruhn, 2003); the uptake of veterinary medicines 
=uolvobѴv bm|orѴ-m|v Őo-ѴѴ;|-ѴĺķƑƏƏѵőĸ;mbuoml;m|-Ѵv;Ѵ;1|b;
pressure of AMDs on bacteria of importance to public health (Tello, 
v|bmķş$;Ѵ=;uķƑƏƐƑőĸ-m7|_;u;Ѵ;-m1;o=|_;v;bvv;v=ouu;]Ѵ--
|ouvŐ"bm];uķ"_-ķ!_o7;vķş-u|ķƑƏƐѵőĺ
Ecotoxicology is not limited to the measurement of environmen-
tal contamination by AMDs. It involves also the environmental pres-
ence of bacteria and genes of resistance. The spread of resistance 
];m;vbml-mu;-v;-uѴ7o1l;m|;7Ő;;uķ"1_lb||ķş"l-ѴѴ-ķ
2011). Urban wastewater treatment plants are both a major source 
of release of AMDs into the environment (Rizzo et al., 2013) and 
“hotspots” for the admixing of resistant bacteria and genes of resis-
tance from human and veterinary sources. In many locations, waste-
water from slaughterhouses is simply collected with human waste 
in municipal treatment plants, thereby favouring genetic exchanges 
between bacteria of differing sources. Class 1 integrons, genetic ele-
ments which acquire foreign genes from the environment and play a 
central role in spreading antibiotic resistance, can be used as a proxy 
=ou-m|_uoro];mb1roѴѴ|bom ŐbѴѴbm]v;|-ѴĺķƑƏƐƔőĺ |-v;v|bl-|;7
that, depending on the host (food-animal species, human) up to 1023 
copies of class 1 integrons are shed every day into the environment 
with the following ranking: pigs > poultry > cattle >l-mŐ,_;|-Ѵĺķ
ƑƏƐƕőĺ|1-m0;mo|;7|_-||_bvu-mhbm]ou7;u1ouu;Ѵ-|;v;ѴѴb|_|_;






Microbiologists’ contributions to AMDs evolved with time and 
now relate to all aspects of AMR and public health issues, as in-
dicated in previous sections of this review. In early developments, 
microbiologists were the first to report PK data for a range of 
drugs, because assay methods were initially microbiological. The 
most emblematic microbiological growth medium used to meas-
ure plasma concentration of AMDs, but also used for antibiotic 
susceptibility testing and MIC determination, is the Mueller-
Hinton Broth (MHB), which was co-developed by the microbi-
oѴo]bv| o_m o-u7 ;ѴѴ;u -m7 |_; ;|;ubm-u v1b;m|bv| -m;
Hinton at Harvard University (Figure 11).
$_;7bv1o;u bm -r-m bm |_; Ѵ-|; ƐƖƔƏv |_-| u;vbv|-m1; |o -
set of four or more antibiotics could be transferred by cell-to-cell 
contact, that is by conjugation, between Enterobacteriaceae of the 
same or of different species, marked a major advance in the un-
7;uv|-m7bm]o=!-m7 b|v blrѴb1-|bomv Ő)-|-m-0;şh-v--ķ
ƐƖѵƐőĺ$_;v;;-uѴ v|7b;vv_o;7 |_-| ľbm=;1|b;Ŀ u;vbv|-m1;7;-
terminants, initially called R-factors, were episomal, and could 
therefore exist and replicate independently of the bacterial chro-
mosome. Later, it transpired that these R-factors were circular 
pieces of DNA, which were then referred to as R-plasmids, accord-
ing to the term introduced by Lederberg in 1952 (Lederberg, 1952). 
m |_; ƐƖѵƏvķ |_; blr-1| o= |u-mv=;u-0Ѵ; -m|b0bo|b1 u;vbv|-m1; om
public health was increasingly recognized, and many authors sug-
gested that the use of antibiotics in livestock, for example tetracy-
clines in pig and fowl diets, could contribute to the emergence and 
7bvv;lbm-|bomo=u;vbv|-m|0-1|;ub-Őm7;uvomş	-||-ķƐƖѵƔőķŐv;;
";1|bomƑĺƐőĺ
The contribution of microbiologists has passed through stages 
of technical and methodological innovations, notably in the rapid 
identification of bacteria and their sensitivity to AMDs. The 
state-of-the-art methodologies for identification and suscepti-
bility testing of veterinary pathogens has recently been reviewed 
Ő-u7-0-vvb ;| -ѴĺķƑƏƐƕőĺ	Ŋ$ Ől-|ubŊ-vvbv|;7 Ѵ-v;u7;-
vour|bomņbomb-|bomŊ|bl;o==Ѵb]_|ől-vvvr;1|uol;|uŐ"őbvmo
used routinely to identify species of bacteria within minutes. 
_;mo|rb1 m|blb1uo0b-Ѵ "v1;r|b0bѴb| $;v|bm] Ő"$ő -v -m7
remains the cornerstone for individual diagnostic tests for AMR. 
The conventional approach, using disk diffusion or broth dilu-
|bomķ bmoѴ;v - 7;Ѵ- o= vol; ƓѶŋƕƑ _u |o o0|-bm - u;vѴ|ĺ $_bv
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who co-developed a protein-free medium for the isolation of 
gonococcus and meningococcus, now known as the Mueller-Hinton 
-]-uņ0uo|_Ő;ѴѴ;uşbm|omķƐƖƓƐőĺ$_bv1Ѵ|u;l;7bl1om|bm;v
to be widely used to test bacterial susceptibility to antimicrobial 
drugs
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Őu;vѴ| o0|-bm;7b|_bm Ѷ _uő Ő-m;Ѵhl ;| -Ѵĺķ ƑƏƑƏőĺ m r-u-Ѵ-
lel, several nonphenotypic new technologies, including those 
based on molecular and genome sequencing, are being developed 
(Vandenberg et al., 2020).
Molecular AMR detection methods specify resistance genes and 
u;vbv|-m1;Ŋ1om=;uubm]l|-|bomv Ő-m;Ѵhl;|-ѴĺķƑƏƑƏőĺ)_oѴ;Ŋ
];mol;v;t;m1bm]Ő)"őruob7;v]Ѵo0-Ѵbm=oul-|bomom|_;ru;v-
ence of all resistance genes in a given sample (resistomes analysis). 
)"-Ѵvo;m-0Ѵ;v1_-u-1|;ub-|bom-m71olr-ubvomo=bvoѴ-|;v=uol
several animal species, including humans, and hence documentation 
of phylogenetic similarities and epidemiological relationships among 
bvoѴ-|;vĺ |_;v;l;-mvķ)"1-m0;ru;7b1|;7 |o blruo;!
surveillance and interpretation on the transmission of resistant bac-
teria and AMR genes throughout the food chain. The potential is for 
)"|ou;rѴ-1;|u-7b|bom-Ѵr_;mo|rb1l;|_o7v=ouuo|bm;vu;bѴ-
lance of AMR (Collineau et al., 2019).
Using these new and older methodologies, a multitude of data 
has been generated over the last four decades, leading to the cur-
u;m|v|-|;o=!hmoѴ;7];ĺou|_;r;ubo7ƐƖƕƔŋƑƏƐƔķ"1_-uķ
mm;ķ -m7 -m 	bfh;u;m ŐƑƏƐѵő bm - u;b; ;m|b|Ѵ;7 ľƓƏ ;-uv o=
;|;ubm-ur-r;uv bmoum-Ѵo=m|blb1uo0b-Ѵ_;lo|_;u-rŌ_-|
have we learnt?” summarized the contributions of microbiolo-
gists. Among others, contributions of major impact were those of 
oѴl0;u]ķ v|;u_oѴlķ ";m];uķ -m7 o_;m ŐƐƖѶƓőķ m]0;u] ŐƑƏƏƐőķ
1;m-m7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ŐƑƏƏƓőķ -vl-mķ;bvķ (;Ѵ7l-mķ Ѵ;v;mķ -m7 -u;v|ur ŐƑƏƏƔőķ







all aspects of AMD discovery, development, use and regulation, but 
most particularly to epidemiology (vide infra). Microbiologists have 
also been whistle-blowers, challenging certain practices and thereby 
leading veterinary medicine to define more prudent uses of AMDs. 
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equivocally prove the relationship between AMD uses in animals 
and the emergence of AMD resistance in humans, as discussed in 
";1|bom ƑĺƐĺ  7bu;1| ;rb7;lboѴo]b1-Ѵ u;Ѵ-|bomv_br 0;|;;m -mbl-Ѵ
-m7=-ul;u0-1|;ub-Ѵ bvoѴ-|;vķ |_-| bv-ruo=;vvbom-Ѵ ubvh Őv|-=vom
şo;mķƐƖƖƕő-v 1om=bul;7;-uѴ =ou!" bmrb]v -m71-||Ѵ;
Ő-m|;mķƐƖѵƒő-m7-ѴvobmroѴ|uŐѴ7;uv;|-ѴĺķƑƏƐƏőĺ$_;rov-
sibility of a more global (community) risk was clearly demonstrated 
by two emblematic events: first, the use of nourseothricin as a feed 
additive and, second, the misuse of ceftiofur in Canadian hatcheries.
Nourseothricin is a member of the streptothricin class of ami-
mo]Ѵ1ovb7;	v|_-|-vv;7omѴbm-v|;ul-mķ-v-]uo|_
ruolo|;ubmrb]vĺ;|;;mƐƖѶƒ-m7ƐƖƖƏķlb1uo0boѴo]bv|v;u;bm
a position to trace a transposon-encoded streptothricin gene of re-
vbv|-m1;Őbu1__;ѴѴ;ķƑƏƐѶ0őĺ=|;u|o;-uvĽv;ķrѴ-vlb7Ŋ0oum;u;-
sistance to streptothricin occurred in E. coli from nourseothricin fed 
pigs. More importantly, there was evidence of widespread dissem-
ination of resistance in manure, river water, food and the g.i.t. flora 
of farm employees, their family members, healthy outpatients not 
related to animal husbandry and in urinary tract infections (Hummel, 
$v1_࢜r;ķş)b||;ķƐƖѶѵőĺm-77b|bomķ|_;u;vbv|-m1;7;|;ulbm-m|-v
detected in Salmonella and Shigella strains isolated from human diar-
u_o;-1-v;vŐ$v1_-r;ķƐƖƖƓőĺvShigella is a pathogen of primates, 
but does not occur in the g.i.t. of swine, it was deduced that the 
horizontal transfer of streptothricin resistance had occurred in the 
intestinal tract of humans.
A second emblematic case of quasi-experimental epidemiology 
of AMR is that of ceftiofur resistance in Salmonella enterica";uo-u
Heidelberg, harvested from chicken meat and humans in Canada 
Ő	|bѴ ;| -Ѵĺķ ƑƏƐƏőĺ m  ࣐0;1ķ 1_-m];v bm 1;=|bo=u u;vbv|-m1; bm
chicken Salmonella Heidelberg and E. coli isolates were clearly asso-
ciated with changing levels of ceftiofur use in hatcheries (an illegal 
practice in the EU). Moreover, this change mirrored the incidence 
of human infections from ceftiofur-resistant Salmonella Heidelberg. 
)_;m1;=|bo=u-vv;7ķ|_;ru;-Ѵ;m1;o=1;=|bo=uu;vbv|-m1;bvo-
Ѵ-|;v =uolu;|-bѴ1_b1h;m-vr|oѵƑѷ=ouSalmonella, decreasing 
|oƕѷ-=|;u |_;oѴm|-ub|_7u--Ѵo= 1;=|bo=uķ |_;m bm1u;-vbm]
-]-bm|oƑƏѷ-=|;u b|v u;Ŋbm|uo71|bomĺѴvo7ubm]|_bvr;ubo7ķ |_;
incidence of ceftiofur-resistant Salmonella Heidelberg in human in-
=;1|bomvbm ;0;1-vƒѵѷķ_;m1;=|bo=u-vbmv;ķ7;1u;-vbm]
|oѵѷ-=|;ub|vb|_7u--Ѵ-m7bm1u;-vbm]-]-bm|oƐƑѷ-=|;u-r-u|b-Ѵ
re-introduction of ceftiofur in hatching.
These case studies were related either to a now banned EU prac-
tice (use of AMDs as growth promoters) or to the misuse of an AMD 
(ceftiofur use in hatcheries). It was not until the 1990s that more 
global threats, associated with approved therapeutic uses of veter-
bm-u	vķ;u;0;||;u-rru;1b-|;7ĺ mƐƖѶƕķ-mou-Ѵ=oulѴ-|bom
of enrofloxacin for the treatment of respiratory poultry infections 
due to Mycoplasma spp. and Pasteurella multocida was launched in 
|_;;|_;uѴ-m7vĺѴlov|ƐƏ ;-uv Ѵ-|;uķ bmƐƖƖѵķ ;muo=Ѵo-1bm-v
-rruo;70&"	=ou|_;u;71|bomo=lou|-Ѵb|-vvo1b-|;7b|_
E. coli in poultry. This had rapidly led, both in the EU and United 
"|-|;vķ |o |_; ;l;u];m1; o= u;vbv|-m1; bm =oo7Ŋ0oum; r-|_o];mv
(Campylobacter spp. and Salmonella spp.). Enrofloxacin is closely re-
lated to ciprofloxacin, an extensively prescribed fluoroquinolone in 
human medicine. In several domestic species, enrofloxacin is a pro-
drug metabolized to ciprofloxacin. This invalidates the marketing 
1om1;r|=ou|_;vr;1b;vvr;1b=b1b|o=-;|;ubm-utbmoѴom;ĺ)_;m
ƐѶՊ|Պ ՊՍ LEES Et aL.
-7lbmbv|;u;7bm=;;7ou-|;uķ;muo=Ѵo-1bmu-rb7Ѵbm71;vŐƑƓŋƓѶ_uő
the emergence of fluoroquinolone resistance in Campylobacter jejuni, 
a commensal bacterial species present in the g.i.t. of poultry (van 
o;mķ(;Ѵ7l-mķ7;om]ķş;bvķƑƏƏƒőĺou;o;uķbm=Ѵo1h|u;-|-
l;m|ķm;-uѴƐƏƏѷo=Campylobacter become resistant with a per-
vbv|;m1o=rƓ;;hv-=|;u1;vv-|bomo=|u;-|l;m|Őlr_u;;|-Ѵĺķ
2005). As early as 1990, it was reported in the Netherlands that the 
recorded increase of quinolone resistance in human Campylobacter 
spp. was temporally related with the large-scale use of enrofloxacin 
in veterinary medicine (Endtz et al., 1990). Considering the almost 
exclusive transmission route of Campylobacter from chicken to man, 
by the food chain, it was concluded that the resistance recorded in 
humans was due principally to the use of enrofloxacin in the poultry 
industry (Endtz et al., 1991). In human medicine, campylobacterio-
sis is generally a self-limiting condition, not requiring treatment. In 
some critical circumstances, however, for example in the elderly, in 
immunocompromised patients and in cases of co-morbidity, fluoro-
quinolones and macrolides are the drugs of choice (Yang et al., 2019). 
Even if correlation is not synonymous with causation, this should 
have led at that time to the hypothesis that therapeutic failures in 
human medicine to treat zoonotic infections might have been due 
to the use of AMDs in veterinary medicine, including treatment for 
1-lrѴo0-1|;ubovbvŐb77o1hķƐƖƖѵőĺ
m |_;&"ķ vblbѴ-u;;m|v;u; u;rou|;7 bm |_;;-uv bll;7b-
ately following the introduction of enrofloxacin to treat poultry dis-
;-v;vĺ$_bvѴ;7|_;&"	|o7;1b7;ķbmƑƏƏƏķ|ob|_7u-|_;v;
o=;muo=Ѵo-1bmbmroѴ|uķ|_bv0;bm]-=buv|v1_o11-vbombm|_;&"
regulatory history for an AMD. However, in a commercial setting of 
widespread use food additives, the Agency’s decision was legally 
challenged, and it was not until 5 years later, in 2005, that the ban 
|ooh ;==;1| Őbu1__;ѴѴ;ķ ƑƏƐѶ0őĺ =|;u b|_7u--Ѵ o= ;muo=Ѵo-1bm
=uolv;bmroѴ|u bm|_;&mb|;7"|-|;vķ|_;ru;-Ѵ;m1;o==Ѵouo-
quinolone resistance in Campylobacter jejuni in poultry decreased. 
As predicted, this was also the case for human medicine and, at that 
time, it was thought that this regulatory FDA decision was a major 
v11;vv bm r0Ѵb1 _;-Ѵ|_ |;ulv Ő;Ѵvomķ_bѴѴ;uķ o;uvķşm]Ѵoķ
ƑƏƏƕőĺ mv0v;t;m|;-uv ŐƑƏƏѶŋƑƏƐƐőķ_o;;uķ-m;vu];o=
ciprofloxacin-resistant Campylobacter jejuni from retail chicken was 
u;rou|;7ĺ"blbѴ-uѴbm|_;&ķ7;vrb|;b|_7u--Ѵo==ѴouotbmoѴom;v
as growth-promoting agents, the incidence of fluoroquinolone-re-
sistant Campylobacter jejunibm0uobѴ;uvbm1u;-v;7=uolƔĺƒѷbmƑƏƏƐ
|oƑѵѷbmƑƏƐƒķbm7b1-|bm]|_-||_;0-mmbm]o==ѴouotbmoѴom;v-v
growth promoters per se may not suffice to reduce or eliminate 
reservoirs of resistant bacteria. However, and in contrast with the 
vb|-|bom bm |_;&mb|;7"|-|;vķ |_;	ņ"ņ!u;-
corded no association between the consumption of fluoroquino-
lones in food-producing animals and the occurrence of resistance 
in Campylobacter spp. from cases of human infection (Anonymous, 
2015). A similar conclusion was reached for Salmonella (Helke et al., 
ƑƏƐƕőĺ
Now, even with 30 years hindsight on the above case, and several 
o|_;uvu;1;m|Ѵu;b;;7Ő-o;|-ѴĺķƑƏƐѵőķ|_;Ѵbmh0;|;;m;|;ubm-u
and human clinical isolates of Campylobacter remains controversial. 
Recent studies confirm that on farms AMD selection pressure can in-
crease colonization of animals with drug-resistant Campylobacter spp., 
whilst it is not possible to establish a clear causal relationship between 
AMD use in animals and prevalence of drug-resistant food-borne 
1-lrѴo0-1|;ubovbv bm _l-mv Ő1u-1hbm ;| -Ѵĺķ ƑƏƐѵőĺ | bv hmom
that pressure from AMD use is not the sole factor for the selection 
and dissemination of resistance. Recently, the detection in Australia 
of a sub-population of Campylobacter isolates, exclusively resistant to 
fluoroquinolones, was unexpected, because fluoroquinolones were 




Today, the possibility of transfer of AMR from animals to human is 
no longer debated, but the question remains as to the magnitude of 
the contribution to the overall level of AMR in humans deriving from 
animal uses of AMDs. Many authors have expressed strong, even 
strident, opinions on the implication, or not, of veterinary uses of 
AMDs on AMR prevalence in humans. Moreover, the opinions have 
generally been highly polarized. For example, it was suggested that 




suggestion that veterinary medicine, rather than human medicine, 
was the primary factor responsible for AMR in humans. He further 
suggested that restrictions on animal use would actually be ineffec-
tive. The opposing view has been to criticize the veterinary use of 
AMDs, impressing on the debate their interpretation of literature 
7-|-ĺm;-lrѴ;u;Ѵ-|bm]|o!bv|_;;v|bl-|;o=ƐķƔƐѶ-77b|bom-Ѵ
deaths per year resulting from cephalosporin and other AMD usage 
in poultry, with the wholly unsubstantiated claim that the number of 
avoidable deaths and the costs of healthcare potentially caused by third-
generation cephalosporin use in food animals is staggering (Collignon, 
-u;v|urķubmķş1;mķƑƏƐƒőĺ
In addressing this debate, with its opposing factions, the crucial 
role of epidemiologists is now to describe and quantify the relation-
ships between AMD field use, including amounts consumed and 
conditions of field use and AMR emergence (Chantziaras, Boyen, 
-ѴѴ;mvķş	;Ѵ=ķƑƏƐƓőĺ m7;;7ķ |_bv!-mbl-Ѵŋ_l-m7;0-|;
was not and is not merely a speculative ethereal exercise. Many 
jurisdictions have implemented restrictions on the use of AMDs in 
agriculture, and they have been influential in promoting the con-
1;r|o=	v1ub|b1-Ѵ|o_l-ml;7b1bm;ķ=ou;-lrѴ;0|_;)
ŐmomlovķƑƏƐѶ;őĺ
If these polarized debates are to progress to satisfactory conclu-
sions, more nuanced approaches, based on advances in epidemio-
logical methodologies will be used when available. The application 
o=)" bv ;r;1|;7 |o vrrou| lou; o0f;1|b; -m7 -11u-|; ubvh
assessments of food-borne AMR, based on quantitative microbial 
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risk evaluation, adopting Codex Alimentarius principles for conduct-
ing microbiological risk analysis (Collineau et al., 2019). Indeed, the 
_b]_7bv1ublbm-|ouro;uo==;u;70)"-m-Ѵvbv_-v|_;ro|;m-
tial to attribute cases of food-borne disease to putative sources of 
bm=;1|bomŐ;]-mş;mvomķƑƏƐѶő-v7o"ou1;||ub0|boml;|_o7v
Őbu;vķ	-u|;ķş-Ѵ7ķƑƏƐѶőĺ$_;Ѵ-||;u-u;v|-|bv|b1-ѴѴ0-v;7l;|_-
ods, which estimate the probability that a sample from a given case 
is the source (donor) of infection for another case (recipient). As an 
example, these mechanistic oriented investigations aim to quantify 
molecular similarities between a multiplicity of reservoirs, as a first 
v|;r |o-u7v "ou1;||ub0|bomķ -v u;rou|;7 u;1;m|Ѵ =ou |_; ;rb-
7;lboѴo] o= "Ŋ -m7 lrŊruo71bm] E. coli Ő"ņlrŊő
Ő	ou-7oŊ-u1झ- ;| -Ѵĺķ ƑƏƐѶőĺ olr-ubvom -1uovv ƑƑ u;v;uobuv
(human, animals, food, environment) of the molecular relatedness 
o="ņlrŊ bm7b1-|;77bv|bm]bv_-0Ѵ;"ņlrŊ|u-mv-
mission cycles in different hosts but failed to demonstrate a close 
;rb7;lboѴo]b1-Ѵ Ѵbmh-];o="ņlr];m;v-m7rѴ-vlb7u;rѴb1om
types between livestock farms and people in the general population 
Ő	ou-7oŊ-u1झ- ;| -Ѵĺķ ƑƏƐѶőĺ $_; -|_ouv v]];v|;7 |_-| Ѵb;v|o1h
reservoirs, including poultry and poultry meat, are not major contrib-
|ouv|o"ņlro11uu;m1;bm_l-mvĺ$_bvѴ-u];7-|-v;|-v
-m-Ѵv;7t-m|b|-|b;Ѵvbm]"ou1;||ub0|boml;|_o7oѴo]ĺ|-v
v_om |_-|lov| 1ollmb|Ŋ-1tbu;7 1-uub-]; o= " ruo71bm]
and plasmid-encoded AmpC (pAmpC)-producing E. coli were attrib-
utable to human-to-human transmission (approximately two-thirds), 
=oѴѴo;70=oo7ķ-mbl-Ѵ-m7;mbuoml;m|-Ѵvou1;vŐ]_bmbŊu-v
et al., 2019). This finding challenges the alarming and unsubstanti-
ated opinions expressed earlier by others (Collignon et al., 2013).
For the future, this methodology for attribution of sources should 
become essential for the development of rational and effective public 
health interventions. In the previous example, although direct contri-
butions of animals were estimated to be smaller than human-to-human 
;1_-m];vķ bm=;1|bomķ1om|-lbm-|bom-m77bvv;lbm-|bomo="v-m7
pAmpCs from nonhuman reservoirs (animal, meat, seafood, raw vege-
tables…) were considered to be sufficiently large to justify their specific 
lomb|oubm]-m7|o;m=ou1;lb|b]-|bomroѴb1Ő]_bmbŊu-v;|-ѴĺķƑƏƐƖőĺ
ƔĺѵՊ|Պ$_;om;_;-Ѵ|_bmb|b-|b;
In 2020, AMR must be regarded as a global ecological problem with 
an animal contribution. Factors determining AMR prevalence and its 
dissemination are numerous. They include both medical and veteri-
nary use, overuse, misuse and abuse of AMDs, as well as nonmedical 
AMD uses (e.g. use of streptomycin in agriculture); and use of other, 
nonantibiotic antimicrobials, such as triclosan and heavy metals, that 
can select for antibiotic resistance mechanisms.
One Health concepts, and their relationship to broad aspects of 
ecology, are now the AMD and AMR paradigms dominating scien-
tific research and public debate, deriving from recognition that AMR 
bv - ]Ѵo0-Ѵ ;1oѴo]b1-Ѵ bvv; o= o;uŊub7bm] vb]mb=b1-m1; Ő;Ѵ0-m7 ş
Laxminarayan, 2015).
Acknowledging the inextricably inter-connected three health 
(animal, human and environmental) issues, Roger K. Mahr, when 
President of the American Veterinary Medical Association (AVMA) 
bmƑƏƏƕķ bmb|;7_bv 1om|;ur-u| bm_l-ml;7b1bm;ķ!om-Ѵ7	-bvķ
then President of the American Medical Association (AMA), to open 
discussions on subjects of common concern. The goal was to find 
common cause between animal and human medical communities. 
$_;m-mblovѴ-7or|;7- ľm;;-Ѵ|_Ŀ u;voѴ|bom bmm;
ƑƏƏƕĺ$_;bmb|b-|b;|-vh=ou1;7;=bm;7m;;-Ѵ|_-vľ|_;1oѴѴ-0o-
rative efforts of multiple disciplines working locally, nationally, and 
globally, to attain optimal health for people, animals and our envi-
ronment.” The document entitled “One Health: A New Professional 
lr;u-|b;ĿŐmomlovķƑƏƏѶő7;v1ub0;v|_;]o-Ѵv-m7-rruo-1_;v
o=|_;m;;-Ѵ|_bmb|b-|b;ĺ"bm1;ƑƏƏѶķ|_;&_-v-Ѵvoruolo|;7
the One Health approach, with concept integration into EU docu-
ments, such as that entitled “One Health: Addressing health risks 
at the interface between animals, humans and their environments” 
(Anonymous, 2013).
In the conceptual framework of One Health, politicians seek 
scientific expertise, including answers to complex, multi-factorial 
problems. The longer term response from the scientific community 
therefore demands a multi-factorial approach and, in particular, 
global solutions to global problems. This is required to address pre-
7b1|bomvņv1;m-ubovķv1_-v|_ov;o=|_;)Ő"_-ѴѴ1uovvş	-b;vķ
ƑƏƐƓőĺ $_;bu 7oolv7- v1;m-ubo o= |_; ouѴ7 bm ƑƏƔƏ -v 0-v;7
on predictive models, which assumed no alteration of course for 
the global AMD ship. The predicted consequence of inaction was 
as follows: “Armageddon” for the effective treatment of infectious 
diseases; consequential “losses of life and increased suffering”; and 
associated “astronomical financial costs.” The necessary response, 
initially and encouragingly, has been the requisitioning of, reflections 







In the EU, awareness of the dangers of AMR was clearly expressed 
and the principles underlying solutions were described follow-
ing a conference entitled “The Microbial Threat.” This invitation 
1om=;u;m1;ķ _;Ѵ7 bm or;m_-];m bm ƐƖƖѶķ l-7; ! -m o==b1b-Ѵ
EU concern for the first time. The initiative yielded a set of con-
clusions which, together with a summary of the conference, were 
r0Ѵbv_;7 -v or;m_-];m u;1oll;m7-|bomv Őmomlovķ ƐƖƖѶőĺ
Recommendations included the surveillance of AMR and monitor-
ing the use of AMDs in both animals and humans. In animals, it was 
proposed that surveillance should be focussed on potential transfer 
ƑƏՊ|Պ ՊՍ LEES Et aL.
of resistant, zoonotic, food-borne pathogens and resistance genes to 
humans (Mevius et al., 1999). This initiative was shortly followed by a 
recommendation from the Council of the EU in 2001 urging member 
states to follow and adopt the recommendations of the Copenhagen 
meeting. Funding from EU research funds was then provided for 
projects to monitor resistance and the use of AMDs, which, until 
then, had been lacking in most EU countries. This initiative is a good 
example of a major health problem raised by concerted and official 
&-1|bomŐublo7|ŊpѴѴ;uķƑƏƏƓőĺ
$o & 1om1;u|;7 -1|bomv Ő& Ɠth and 5th Framework pro-
grammes) were established to create a network of national veter-
inary reference laboratories in Europe and establish a surveillance 
system for monitoring AMR of animal origin. The first action, named 
“Antibiotic Resistance in Bacteria of Animal Origin” (ARBAO I), 
aimed to establish the state-of-the-art and promote standardiza-




riod 2003-2005 was co-ordinated by Frank Aarestrup; its objective 
was to create a stable EU network for generating comparable and 
u;ru;v;m|-|b;7-|-om!Ő;m7ubhv;mķ;bvķ"1_uo;|;uķ$;-Ѵ;ķ
oķ;|-ѴĺķƑƏƏѶőĺ
Industry has also been involved in surveillance. VetPath is an 
ongoing Pan-European resistance monitoring programme, encom-
passing food-borne bacteria and target pathogens of food-pro-
71bm]-m71olr-mbom-mbl-ѴvŐѴ-u1_;|-ѴĺķƑƏƐѵĸ7;om];|-Ѵĺķ
2013). In addition, there are national, not harmonized, surveillance 
v1_;l;v =ou lomb|oubm] ! =ou r-|_o];mb1 0-1|;ub- Ő"1_ubf;u
;|-ѴĺķƑƏƐѶőĺ
These initiatives have been followed by a multitude of others, 
emanating from a range of professional, national and international 
organizations; these bodies have developed, within the framework 
of their missions and strategic axes, guidelines aimed at limiting the 
development of AMR and/or promoting good therapeutic practices. 
Moreover, many organizations, representing veterinary clinical 
groups, for example on species’ bases, have issued guidelines to their 





The United Nations involvement with AMD and AMR is chan-
nelled through two organizations, namely the Food and Agriculture 
u]-mb-|bomŐő-m7|_;)ouѴ7;-Ѵ|_u]-mb-|bomŐ)ő;-1_
served by several committees.
$_;-v;v|-0Ѵbv_;7bmƐƖƓƔĸ b|v_;-7t-u|;uv bv bm!ol;ķ
Italy. For FAO, the Codex Alimentarius Commission (CAC) is the 
committee charged with developing harmonized international food 
standards to protect consumer health, and the Codex Committee 
on Residues of Veterinary Drugs in Foods (CCRVDF) is specifically 




of risk analysis, to assess and manage risks to human health asso-
ciated with the presence in food and feed (including aquaculture) 
of antimicrobial-resistant microorganisms and their onward trans-
mission through food and feed. A second Task Force, established in 
ƑƏƐƕķ_-v|_;u;lb|o=7;;Ѵorbm]]b7-m1;=ou|_;l-m-];l;m|o=
AMR in the food chain.




also recommends MRLs for target tissues and determines criteria for, 
and evaluates methods of, analysis for detecting and/or quantifying 
residues in food. It provides independent scientific advice to Codex 
on residues of veterinary drugs, facilitating recommended MRLs by 
CCRVDF. More specifically for AMDs, it establishes microbiological 
ADIs, to be considered alongside conventional “toxicological ADI.” 
The lower of the two ADIs is selected as the final ADI (Boobis et al., 
ƑƏƐƕőĺ o7; bvv;7 o7;v o= u-1|b1; |o bmblb; -m7 om|-bm
m|blb1uo0b-Ѵ!;vbv|-m1; bmƑƏƏƔ -m7b7;Ѵbm;v =ou!bvhm-Ѵvbv
of Foodborne Antimicrobial Resistance in 2011 (“Antimicrobial 
!;vbv|-m1;Ň	*$!&"Ŋ)ĿƑƏƐƖőĺ
ѵĺƒՊ|Պ$_;)ouѴ7;-Ѵ|_u]-mb-|bomŐ)ő
) -v ;v|-0Ѵbv_;7 bm ƐƖƓѶĸ b|v _;-7t-u|;uv -u; bm ;m;-ķ
"b|;uѴ-m7ĺ) _-v ;;u|;7 - 7;1bvb; bm=Ѵ;m1; om 	 ;|-
;ubm-u v;vķ o;uv; -m7lbvv; ru-1|b1;vĺ $_;) 7o1l;m|
“Optimal use of antimicrobial medicines in human and animal health” 
7;1Ѵ-u;v bm0f;1|b;ƓĹOptimize the use of antimicrobial medicines 
in human and animal healthŐľ)ŇѴo0-Ѵ-1|bomrѴ-mom!Ŀőĺ
clear goal is to adopt measures which preserve the effectiveness of 
AMDs of importance for human medicine by reducing their usage in 
-mbl-Ѵvĺ)Ѵ-m1_;7b|vr7-|;7]b7;Ѵbm;vomv;o=l;7b1-ѴѴ
blrou|-m|	v bm =oo7Ŋruo71bm]-mbl-Ѵvomƕo;l0;uƑƏƐƕĺ
These recommend first, that farmers and the food industry cease 
routine usage of drugs to promote growth (as required in the EU 
=uolƑƏƏѵő -m7 v;1om7ķ |_-| ;|;ubm-ub-mv 1;-v; v-]; bm 7bv;-v;
prevention in healthy animals (i.e. prophylaxis).
oll;m1bm]bmƑƏƏƔķ)_-vu;Ѵ;-v;7Ѵbv|vo=	v1ub|b1-ѴѴ
blrou|-m|=ou_l-ml;7b1bm;Ő)bv|őŐmomlovķƑƏƐƖ_őĺ
$_;) 1Ѵ-vvb=b;v 1uu;m|Ѵ v;7	v bm _l-mv -m7 -mbl-Ѵv
in three categories, based on their relative importance in human 
l;7b1bm;Ōľblrou|-m|ķĿ ľ_b]_Ѵ blrou|-m|Ŀ -m7 ľ1ub|b1-ѴѴ blrou|-
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u;1;m|1om|uo;uvb-Ѵ|orb1=ou)1om1;umv|_;v;-m7u;]-
ulation of colistin. Colistin has been used in pig medicine for many 
years, and colistin resistance in bacteria from animals has been de-
scribed (Kempf et al., 2013). Rhouma et al. have reviewed the role 
of colistin in pig production, outlining its chemistry, mechanisms of 
action and resistance emergence, as a contribution to One Health 
r;uvr;1|b;v Ő!_ol-ķ ;-7uķ $_࣐ub-Ѵ|ķ ş ;|;ѴѴb;uķ ƑƏƐѵőĺ m
ƑƏƐѵķ b ;| -Ѵĺ ŐƑƏƐѵő u;rou|;7 |_; ;l;u];m1; o= |_; =buv| rѴ-v-
mid-mediated colistin resistance gene, Mcr-1 in Enterobacteriacea 
isolated from animals and humans in China. Olaitan, Morand, and 
!oѴ-bmŐƑƏƐѵőu;rou|;7|_;;l;u];m1;o=1oѴbv|bmŊu;vbv|-m|0-1|;ub-
in humans with no colistin usage, describing this as “a new worry and 
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dation was to uphold the veterinary use of colistin with an objective 
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those AMDs critically important in human medicine. However, the 
effectiveness of the accompanying proposed restrictions is unclear. 
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rectly address these questions, that is does limiting the use of AMDs 
in food animals reduce either the presence of AMR genetic determi-
nants or AMR bacteria first in food animals and then in humans. In 
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was concluded: that restriction of AMD use in food-producing ani-
mals led to a reduction of AMR in these animals; that a smaller body 
of evidence indicated a similar association in human populations, 
particularly those with direct contact with food-producing animals; 
that the implications for the general human population are unclear, 
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fice to enable a meta-analysis. It was concluded that limiting AMD 
use in food animals not unexpectedly reduces AMR in food animals 
and probably reduces resistance in humans also but the magnitude 
of the latter effect could not be quantified.
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French name of, Office International des Epizooties (OIE).
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Health but retained its historical OIE acronym. From 2010, OIE be-
came increasingly focussed on the “One Health” paradigm includ-
ing AMR. OIE developed a strategy to support Member Countries 
Ő1uu;m|Ѵml0;ubm]ƐѶƑőbm-vv;vvbm]-m7l-m-]bm]!ĺruo-
motes surveillance and supports good governance, for enforcing the 
prudent use of AMDs in developing countries. A OIE guideline on 
the harmonization of national AMR monitoring and surveillance pro-
grammes in animals and animal-derived foods has been developed 
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et al., 2001). OIE also manages a database to establish global 
surveillance of AMD usage in animals, monitoring both drug type 
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had regulations in place banning the use of AMDs for use in growth 
promotion. OIE has claimed an international consensus that such 
use should be phased out globally, with immediate universal revoca-
tion of use for growth promotion purposes of those AMDs listed by 
|_;)-vb]_;v|uboub|ub|b1-ѴѴlrou|-m|7u]v=ou_l-m
l;7b1bm;ĺm1|o0;uƑƏƐѶķ-|-uu-h;v_Őouo11oőķ1om;m;7
a meeting of worldwide leaders in animal health, with the remit of 
addressing the global rise of AMR in the animal farming sector.
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Health concept (Figure 5). The Partnership drives the development 
of policies and tools to support measures within Member Countries 
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The European Medicines Agency (EMA) was created in 1995. 
Previously, regulations had been nationally based.
In 2020, combatting the threat of AMR is a high priority for 
EMA and its Committee for Medicinal Products for Veterinary 
&v; Ő(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veterinarian and microbiologist. He was the founder and first 
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on Antimicrobials of the Committee for Medicinal Products for 
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prudent use of AMDs in animals, collecting data on their veterinary 
use in the EU and providing scientifically based recommendations 
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lished a revised CVMP guideline on demonstration of efficacy for 
veterinary medicines containing AMD substances (Anonymous, 
ƑƏƐѵ-őĺ $_bv v;1om7 u;bvbom o= |_; 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information on the use of AMDs in animals that are at risk of being 
infected (metaphylactic use).
Developing and monitoring policies on the responsible use of 
	vbm&;l0;u"|-|;v7;r;m7vom1oѴѴ;1|bm]-11u-|;7-|-om
usage. At the request of the EU Commission, a harmonized approach 
for collecting and reporting data on AMD use in animals from EU 
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started monitoring AMD use in 2010 by enforcing the European 
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project to identify possible risk factors that might lead to the de-
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quantities of veterinary AMDs sold are linked to animal demograph-
ics in each country. To normalize the sales data for the animal pop-
ulation subjected to treatment with AMDs, a population correction 
mb|Ő&őbvv;70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The implementation of resistance monitoring in bacteria respon-
vb0Ѵ;=ou=oo7Ŋ0oum;oomov;v1oll;m1;7bm|_;ƐƖѶƏv0m-|bom-Ѵ
initiative. Following Directive 2003/99/EC on the monitoring of zoo-
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monitor and report AMR in Salmonella and Campylobacter isolates 
from animals and food. In contrast, the monitoring and reporting 
of AMR data from the indicator organisms E. coli and enterococci 
is voluntary. These data are now stored centrally by the European 
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established as an independent EU agency in 2002. Its mission is to 
provide objective scientific advice on any matters having impact on 
food and feed safety. Its remit includes AMR. To execute its mis-
vbomķ"-]]u;]-|;v-m7-m-Ѵv;v-mm-ѴѴ|_;7-|-om!ĺ |v
annual survey encompasses: zoonotic Salmonella and Campylobacter 
isolates from humans, food and animals and; indicator E. coli and en-
terococci isolates from animals and food. Data on methicillin-resis-
tant Staphylococcus aureus in animals and food are also included. For 
|_bv|-vhķ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Prevention and Control (ECDC). ECDC is an EU agency based in 
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strengthen Europe’s defences against infectious diseases.
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tential relationship between the consumption of AMDs by humans 
and animals and the occurrence and incidence of AMR. They deliver 
their findings in joint inter-agency antimicrobial consumption and re-
vbv|-m1;-m-ѴvbvŐ!őu;rou|vŐmomlovķƑƏƐѶ0őĺ
EMA supports the EU Commission’s action plan against the ris-
ing threats from AMR by providing scientific input and advice on 
impacts of using AMDs in animals in partnership with other rele-
-m|&0o7b;vĺ$_bvbm1Ѵ7;v-fobm|orbmbomb|_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to reduce the use of AMDs in animal husbandry (also known as the 
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European Commission requested EMA to update the Antimicrobial 
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the corresponding EU human committee, that is the Committee for 
Medicinal Products for Human Use (CHMP). CVMP issued a discus-
sion document on the categorization of AMDs, to be followed by 
final guidelines. It includes new drug classes, additional categoriza-
tion criteria and the availability of alternatives to AMDs in veterinary 
l;7b1bm;ŐmomlovķƑƏƐѶ-őĺ
For all novel AMDs, there are necessary regulatory hurdles 
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EMA/CVMP has issued a discussion document on proposed catego-
ub;vo=v;bm;|;ubm-ul;7b1bm;Őņ(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(Anonymous, 2019a). These or modified classes of use (after comple-
tion of consultations) will form the basis of AMDs in veterinary use in 





for Veterinary Medicine (CVM) are the principal bodies involved 
in regulation of AMDs. The FDA mission statement is “Protecting 
Human and Animal Health.” FDA is responsible for the Marketing 
Authorisation of AMDs and establishing MRLs/tolerances in food 
products. FDA also conducts research in the areas of its remit. 
)_bѴv|bml-m=b;Ѵ7v	rѴ-v-Ѵ;-7;uv_bruoѴ;-m7bv-||_;=ou;Ŋ
front of regulatory science and policy, this is not the case for AMR in 
veterinary medicine. This is due, first, to the difficulty of regulating 
the use of AMDs as growth promoters and, second, to the fact that 
the FDA cannot, by its constitution, formally require the submission 
of PK data for food animal drug applications. In consequence, FDA 
cannot (in contrast to EMA) issue specific guidance, for example to 
promote PK/PD integration and modelling approaches for the de-
sign of rational AMD dose schedules, unless data from applicants 
are supplied.
m ƑƏƐѶķ 	 u;Ѵ;-v;7 b|v 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is to eliminate production uses of medically important antimicrobials 
and to encompass all remaining therapeutic uses under the oversight 
of licensed veterinarians. The FDA approach was based on the belief 
that a collaborative approach involving all stakeholders would be the 
tb1h;v|-|oblrѴ;l;m||_;u;tbu;71_-m];vbm&"ķ-vo|Ѵbm;7
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ing regulatory action was preferred to the alternative of proceeding 
laboriously on a product-by-product basis, requiring not only addi-
tional resources but also delays to implementation. FDA recognizes 
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that diseased animals require AMD treatment and therefore that drug 
availability must continue for this purpose. In addition, FDA will con-
tinue to authorize AMDs for controlling disease (prophylaxis) being at 
-ub-m1;b|_|_;&bm|_bvu;]-u7ĺmƑƏƐƕķ	ruo71|bombm7b1--
tions (e.g. growth promotion) were withdrawn from all applications 
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CVM has issued several generic guidance documents relevant to 
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New Veterinary Medicinal Products for Food-Producing Animals 
with Respect to Antimicrobial Resistance” (Anonymous, 2019b). 
The body, International Cooperation on Harmonization of Technical 
Requirements for Registration of Veterinary Medicinal Products, 
acronym VICH, provides harmonized technical guidance between 
|_;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veterinary medicinal products intended for use in food-producing 
animals, with regard to characterization of the potential for each 
AMD to select for resistant bacteria of human health concern. An 
blrou|-m| &" 7o1l;m| bv 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of Medically Important Antimicrobial Drugs in Food-Producing 
Animals” (Anonymous, 2019c). This FDA document provides the 
framework for the voluntary adoption of practices to ensure appro-
priate and judicious use of medically important AMDs in food-pro-
ducing animals.
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itors AMR through a tracking platform, comprising multiple net-
works, including the National Antimicrobial Resistance Monitoring 
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system for tracking changes in antimicrobial susceptibility of enteric 
(intestinal) bacteria in sick people (CDC), retail meats (FDA) and food 
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Many other jurisdictions have addressed issues of AMD use and 
AMR emergence in veterinary medicine. An example is the ban on 
fluoroquinolones for food-producing animals in Australia (Cheng 
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health surveillance of antimicrobial-resistant bacteria isolated from 
humans, animals, food and the environment. Co-operative links have 
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Babington Macaulay, who had no scientific training, described a se-
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ceeded best in cases of small-pox. By this discovery 
he saved the lives of hundreds of thousands and we 
venerate his memory for it, though he never heard of 
inoculation… Montague brought inoculation into use; 
and we respect her for it, though she never heard of 
-11bm-|bomĺ ;mm;u bm|uo71;7 -11bm-|bomĸ ; -7-
mire him for it, although some still safer preservative 
should be discovered. It is thus that we ought to judge 
of the events and the men of other times. They were 
behind us… but the question with respect to them is 
not where they were but which way they were going… 
were their faces set in the right or the wrong direc-
tion?… It is the fundamental law of the world in which 
we live that truth shall grow, first the blade, then the 
ear, after that the full corn in the ear.
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These stirring words, outlined almost 200 years ago, have been 
matched by the rapidly evolving uses of AMDs in animals over the last 
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